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Abstract 
The current study examined patterns of drug use, associated harms, and access to 
drug treatment among individuals who inject drugs in northern and southern 
Tasmania.  One hundred individuals in the south and 41 in the north were 
interviewed using the Illicit Drug Reporting System paradigm.  Given recent 
community concern regarding methamphetamine, harms were examined as a 
function of likely dependence on methamphetamine by classifying respondents into 
groups based on Stimulant Severity of Dependence scores: no methamphetamine 
use; methamphetamine use, not likely dependent; and methamphetamine use, likely 
dependent.  Differences were found in patterns of use and harms across the state, 
suggesting that generalisation of research conducted in the capital city is not 
appropriate.  Even among a sample engaging in high levels of poly-drug use, certain 
harms were found to be associated specifically with methamphetamine use and 
dependence.  Access to appropriate treatment for methamphetamine use was low 
among those displaying dependence, with the majority of the sample engaging only 
in treatment for opioid use disorders.  Individuals often perceived that they did not 
need treatment, despite negative perceptions of methamphetamine use, and viewed 
treatment options as not efficacious.  Lack of perceived need was also noted as a 
reason for not accessing metal health services despite self-perceived mental health 
problems.  This suggests the importance of education and integrated service delivery 
to ensure that when clients present to mental health or alcohol and drug services both 
substance use and mental health needs are met, especially as co-morbid difficulties 
are common.         
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Understanding patterns of drug use, supply, and associated risks and health 
outcomes has important implications for policy development (Topp & McKetin, 
2003). Specifically, knowing the types of drugs that are available and accessible can 
inform the development of relevant drug education resources.  Secondly, knowing 
the risks associated with drug use can inform risk reduction strategies and identify 
ways to improve current service provision.  For example, previous research on 
patterns of drug use indicated that the types of drugs injected in Tasmania differ 
substantially from the rest of Australia, due to Tasmania’s isolation from mainland 
drug markets.  This information has been used to inform policy around the types of 
injecting equipment made accessible to people who inject drugs in Tasmania (Topp 
& McKetin, 2003).  Lastly, examination of physical and mental health outcomes 
associated with drug use can assist in identification of needed services to reduce the 
impact of such issues.  Overall, research examining trends in the drug market is 
important to ensure that policy is well informed and that resources can be 
appropriately allocated to areas of need. 
Methamphetamine as a Drug of Concern 
One potential area of need that has been the focus of Australian media, 
policy, and research in the past 12 months is the reduction of risks and harms 
associated with methamphetamine use to individuals and communities.  There are 
several different forms of methamphetamine available to consumers in the illicit 
drug market in Australia, including powder, base, and crystalline forms (Degenhardt, 
Sara, et al., 2016; Topp, Degenhardt, Kaye, & Darke, 2002).  Powder 
methamphetamine, often denoted “speed” is a low to medium purity form of 
methamphetamine that may appear as a white, yellow, orange, pink or brown powder 
(Topp et al., 2002).  Base methamphetamine is often of high purity and appears as a 
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yellow or brown sticky or oily powder, paste or crystal (Topp et al., 2002).  Base 
methamphetamine is formed when the oil obtained from the pseudoephedrine to 
methamphetamine conversion is unsuccessfully purified into methamphetamine 
hydrochloride, with the final product containing many organic impurities (Topp et 
al., 2002).  Crystalline methamphetamine, commonly known as “ice,” is a high to 
extremely high purity preparation of methamphetamine hydrochloride salt which 
appears in the form of large translucent or white crystals or coarse powder 
(Degenhardt, Sara, et al., 2016; Topp et al., 2002).  Crystalline methamphetamine 
provides a stronger dose, more intense effects, and is associated with a higher risk of 
dependence and harms than the powdered form (Degenhardt, Sara, et al., 2016).   
During 2015 there was growing concern that use of methamphetamine, in 
particular the crystalline form, has reached “epidemic” levels (Degenhardt, Larney, 
et al., 2016).  Media reports have been focused on increased ease of access to and 
low cost of the crystalline form of methamphetamine, along with apparent associated 
increases in violence and motor vehicle accidents (Usher, Clough, Woods, & 
Robertson, 2015).  Examination of data from drug-monitoring systems  (e.g., 
Degenhardt, Sara, et al., 2016; Lim, Cogger, Quinn, Hellard, & Dietze, 2015; 
Stafford & Burns, 2015) and national household surveys (Australian Institute of 
Health and Welfare, 2014) suggest prevalence of methamphetamine use in Australia 
has not increased in the general community, rather shifts from use of the lower 
potency powder form to the crystalline form among those already using 
methamphetamine may account for increased methamphetamine-related harms 
observed.  Additional support of this trend is the observed increased purity of 
methamphetamine seized by police in recent years (Degenhardt, Sara, et al., 2016).  
This pattern differs across different groups of individuals using methamphetamine, 
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with decreased use of methamphetamine generally observed in the past two years, 
and relatively stable low proportions of use of the crystalline form, among people 
who frequently use ecstasy and other related psychostimulants (Sindicich, Stafford, 
& Breen, 2016).  This is in contrast to increases in use of crystalline form observed 
among people who inject drugs (Stafford & Burns, 2015).  This shift toward use of 
the crystalline form of methamphetamine is not a new trend and appears to have 
started between the late 1990s and early 2000s (Degenhardt, Sara, et al., 2016).    
Degenhardt, Larney, et al. (2016) argue that while there have been 
disagreements between researchers and media and members of law enforcement 
agencies as to whether methamphetamine use has increased or remained stable, it is 
more important to consider those that are regular and dependent users of 
methamphetamine, as it is these individuals who are most likely to experience harms 
associated with use and thereby impact on society.  The Australian Institute of 
Health and Welfare (2014) reported increased frequency of methamphetamine use 
among those using methamphetamine in 2013 in the National Drug Strategy 
Household Survey, particularly among those using predominately the crystalline 
form.  While small proportions of people who use illicit drugs responding to this 
survey may call into question the validity of these findings they are supported by 
research conducted with such samples.  For example, Stafford and Burns (2015) 
reported increased frequency of injection of crystal methamphetamine among Illicit 
Drug Reporting System (IDRS) respondents across Australia in recent years.  Within 
this sample the proportion of individuals reporting use weekly or more frequent has 
increased (Degenhardt, Sara, et al., 2016).  Degenhardt, Larney, et al. (2016) 
estimated the proportion of regular and dependent methamphetamine users in the 
Australian population between the years of 2002-2014 by multiplying data on the 
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number of individuals receiving treatment for methamphetamine use or being 
hospitalised as a result of use by the proportion of individuals within a samples of 
regular and dependent users who reported receiving treatment for their use and then 
determining what proportion of the Australian population this represented.  They 
estimated that the rates of regular and dependent use had increased in the previous 
five years from 0.74% of the population in 2009/10 to 2.09% in 2013/14 for regular 
use; and 0.47% to 1.24% for dependent use.  This may account for increased 
methamphetamine related harms noted in the Australian community.   
Harms Associated with Methamphetamine  
A number of negative physical and mental health outcomes and other harms 
have been found to be associated with methamphetamine use and dependence.  
Harms related to methamphetamine use in Australia appear to have increased over 
the past five years, with increases in hospital admissions, including for 
methamphetamine induced psychosis or other mental health issues (Roxburgh & 
Breen, 2016); phone calls to helplines (Degenhardt, Sara, et al., 2016); arrest 
(Australian Criminal Intelligence Commission, 2016); and drug treatment episodes 
related to methamphetamines (Stafford & Burns, 2015).  
Repeated use of stimulants such as methamphetamine has been found to 
increase the risk of precursors to heart disease such as thickening and hardening of 
ventricles (ventricular hypertrophy) and arteries and increased fatty deposits in the 
arteries (coronary artery atherosclerosis) (Darke, Kaye, McKetin, & Duflou, 2008).  
Additionally, with repeated use of methamphetamine, especially as the individual 
ages, risk of myocardial infarction (heart attack) also increases (Darke et al., 2008).  
Poly-drug use is also common among individuals using methamphetamine and 
combination with other drugs, including alcohol and opioids such as morphine, can 
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increase the toxicity of methamphetamine and thereby the physical harms associated 
with use (Darke et al., 2008).   
Methamphetamine use is associated with cognitive deficits, especially in the 
domains of sustained attention, verbal memory, and executive functioning  (Darke et 
al., 2008).  In a meta-analysis of the neuropsychological effects of history of 
methamphetamine use disorders, Scott et al. (2007) found moderate magnitude 
effects on learning; executive functioning, especially response inhibition and 
problem solving; episodic memory, information processing speed, and motor skills 
compared to those without a history of methamphetamine use.  Additionally, small 
magnitude effects on attention and working memory, language, and visuospatial 
skills were noted (Scott et al., 2007).  These cognitive effects likely make engaging 
in activities that enlist an individual’s executive functions, motor skills, and 
processing speed, such as driving a motor vehicle more risky, especially among 
those dependent on methamphetamine.   
Co-morbid disorders are commonly reported in individuals with 
methamphetamine dependence, with researchers reporting around one-third being 
diagnosed with an additional psychiatric disorder (e.g., Akindipe, Wilson, & Stein, 
2014).  Particularly common are psychotic, mood, and anxiety disorders (Akindipe et 
al., 2014; Glasner-Edwards et al., 2010b; Salo et al., 2011).  Salo et al. (2011) argues 
that this suggests the need to assess for psychiatric comorbidity in individuals with 
methamphetamine use disorders, and to consider the need to include intervention for 
associated symptoms in addition to treating difficulties with methamphetamine use.   
It seems likely that treatment for methamphetamine use alone will not alleviate mood 
and anxiety symptoms fully especially if they are not substance induced and would 
likely impact functional outcomes for individuals seeking treatment for 
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methamphetamine use.  Researchers have found that comorbid disorders are 
associated with poorer outcomes for individuals who have sought treatment for 
methamphetamine dependence.  For example, Glasner-Edwards et al. (2010a) found 
that those with anxiety disorders had poorer adherence to treatment than those 
without anxiety disorders, and also reported higher levels of methamphetamine use 
three years following treatment for methamphetamine dependence.  They were also 
more likely to have had a hospital admission, medical problems, family problems, 
and suicide attempt.  Likewise, severity of depressive symptoms have been found 
related to treatment adherence and use of methamphetamine at treatment completion 
and poorer psychosocial outcomes (Glasner-Edwards et al., 2009).  Similar findings 
have been found in Australia, with depressive episodes found to be associated with   
increased disability, greater severity of dependence on methamphetamine and higher 
levels of poly-drug use (McKetin, Lubman, Lee, Ross, & Slade, 2011).   
Researchers (e.g., Brecht & Herbeck, 2013; McKetin et al., 2014) have 
identified engaging in violent behaviours as one of the key harms related to using 
methamphetamine.  Brecht and Herbeck (2013) found that methamphetamine use 
was related to engagement in violent criminal behaviours, especially among those 
with more severe dependence and associated problems such as paranoia and 
hallucinations.  Similarly, McKetin et al. (2014) also found self-reported violent 
behaviours such as assaults and damaging property to be associated with 
methamphetamine use, especially among those using the substance more often.  
Victimisation also appears to be associated with methamphetamine use.  For 
example, Darke, Torok, Kaye, Ross, and McKetin (2010) found that risk of being a 
victim of violent crime was greater among those using methamphetamine than the 
general Australian population.   
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McKetin et al. (2014) argue the importance of not generalising research 
findings of harms within one group of people who use methamphetamine to another, 
because different patterns of use may be associated with differing levels of risks and 
related harms.  For example, those who use methamphetamine recreationally and are 
not dependent on the substance are a lower risk group for methamphetamine related 
harms and as such may be less in need of intervention (Darke et al., 2010; McKetin 
et al., 2014).  In support of such arguments, Quinn, Stoové, Papanastasiou, and 
Dietze (2013) found that despite similar sociodemographic characteristics between 
those dependent, compared to those not dependent, on methamphetamine in a sample 
of regular methamphetamine users in Melbourne, dependence was associated with 
higher levels of psychological distress in the past month and current use of 
medication for mental health problems.  Individuals dependent on methamphetamine 
were also more likely to report a history of incarceration and arrest in past 12 
months, as well as to have experienced social, financial, work, study, and legal 
problems in the past six months as a result of use (Quinn et al., 2013).    
It is suggested that higher potency forms of methamphetamine are associated 
with an increased risk for dependence and therefore associated harms such as co-
morbid psychological disorders, poor physical health, increased aggression and 
violence, and neuropsychological deficits (Topp et al., 2002).  McKetin, Kelly, and 
McLaren (2006) found that among regular methamphetamine users in Sydney, those 
using the crystalline form in the past 12 months were nearly twice as likely to be 
dependent on methamphetamine than those using only other forms of 
methamphetamine even when other patterns of use has been adjusted for, such as 
frequency, length of use, and route of administration.  Route of administration of 
methamphetamine also appears to effect the likelihood of developing substance 
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dependence and associated harms. For example, Quinn et al. (2013) in a Melbourne 
sample of people using methamphetamine found that injecting methamphetamine 
over other routes of administration was associated with dependence.  Injecting 
methamphetamine has also been found associated with increased rates of mental and 
physical health problems and unemployment (Novak & Kral, 2011).  These findings 
of increased risk of dependence and associated harms as a function of 
methamphetamine form and route of administration are likely due to the 
pharmacokinetic properties of the drug.  The likelihood of dependence on substances 
is influenced by the amount of drug that reaches the brain, how quickly it reaches the 
brain, and how often the drug reaches the brain (Allain, Minogianis, Roberts, & 
Samaha, 2015).  Routes of administration such as intravenous injection and smoking 
of substances result in the drug reaching the brain more rapidly than other methods 
such as swallowing or snorting the substance and thereby increase dependence risk 
(Allain et al., 2015).  In regard to dose, because the crystalline form of 
methamphetamine is more potent than other forms this likely results in an increased 
dose of the drug entering the brain and therefore increased risk of dependence.        
Overall, prior research into methamphetamine use suggests a number of 
harms associated with this.  However, these harms appear to be more prevalent in 
individuals who use methamphetamine frequently and are dependent on the 
substance and may not apply to those using less frequently and recreationally.  This 
suggests the importance of recognising the need to examine groups of people who 
are dependent and non-dependent on methamphetamine independently, rather than 
assuming a common pattern across all individuals who use methamphetamine.        
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The Illicit Drug Reporting System: Overview and Limitations 
The Illicit Drug Reporting System (IDRS) was established to monitor the 
Australian illicit drug market and associated risks and health outcomes (Stafford & 
Burns, 2014).  It is conducted annually in the capital cities of each state and territory 
in Australia to provide information on emerging drug market trends at both a local 
and national level that may require further examination and identify need for action 
(Stafford & Burns, 2014).  The IDRS comprises interviews with people who 
regularly inject drugs; interviews with key experts in the drug field; and examination 
of indicator data related to drug use such as police drug seizures and treatment 
episodes (Stafford & Burns, 2014). The IDRS is designed as a sentinel study, with 
the assumption that any major new trends in drug markets are likely to first emerge 
in major population centres and amongst those who are heavily engaged in drug 
markets (Stafford & Burns, 2014).    
However, this sentinel approach means that the IDRS is not able to provide 
information on drug markets outside of capital cities, and as this is sometimes the 
sole compilation of substance use data in a jurisdiction, it has been used by policy 
makers to generalise to entire states or territories. This is problematic because 
evidence from multiple sources indicate that patterns of drug use differ as a function 
of geographical area and thus data obtained in capital cities is unlikely to be 
representative of the entire state.  For example, the National Drug Strategy 
Household Survey (Australian Institute of Health and Welfare, 2014) found that 
those who lived in remote and very remote locations were twice as likely to have 
used methamphetamine in the past year than those not living in remote locations.  
Thus, methamphetamine use and related problems may differ in these geographic 
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areas compared to the capital cities surveyed in the IDRS (Degenhardt, Sara, et al., 
2016).   
In Tasmania specifically, there are reasons to expect the drug market would 
differ between the north and south of the state.  For example, de Graaff, Peacock, 
and Bruno (2014) highlight that in the north, access to both sea and airports may 
influence availability of certain types of drugs in the drug market.  Further, the 
establishment of organised motorcycle groups in Launceston may have implications 
for the drug market (de Graaff et al., 2014) as motorcycle groups have been found to 
be involved in the drug market on a national level (Australian Crime Commission, 
2015). While a number of groups have well established positions in the South (e.g., 
the Rebels); others are primarily based in the north of the state (the Black Uhlans, 
Satan’s Riders, Devil’s Henchman); and others (e.g., the Outlaws) are state-wide 
(ABC News, 2015). Thus, with these distinct groups contributing to sources, data on 
the drug market obtained in Hobart through the IDRS are not likely to be applicable 
to people who inject drugs in Launceston.  This has been found to be the case in 
initial IDRS extensions into north and north-west of Tasmania in 2003 and 2006, 
with differences in the patterns of drug use, associated risks and health outcomes 
found across the state (Bruno, 2004; de Graaff & Bruno, 2007).  More recently, the 
Department of Health and Human Services (2014) reported data on the number of 
treatment episodes per month for the period of July 2013 to September 2014 for 
methamphetamine, with a greater number of treatment episodes present in the north 
than the south. This finding is surprising given the smaller population base in the 
north of the state, and suggests that there are some differences between regions in 
terms of problematic methamphetamine use and associated need for treatment.  
Similarly, police drug seizure data indicates differences between regions.  For 
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example, the weight of amphetamine seizures increased in both the north and the 
south from 2013 to 2014.  Amount seized was greater in the south than the north in 
2013, however, in 2014 the north had three times the amount seized in the south.  
Overall, these differences found between regions support the importance of 
examining each area independently, as trends in the north cannot necessarily be 
inferred from data obtained in the south.    
Treatment Access and Barriers 
It is important to explore whether those who are in need of treatment as 
indicated by dependence on substances are able to access treatment.  Previous 
research has indicated low rates of methamphetamine treatment access among those 
likely requiring treatment.  For example, in a Melbourne sample of 
methamphetamine users, less than a third of those classed as dependent on 
methamphetamine were accessing treatment services in relation to their use (Quinn 
et al., 2013).  Wallace, Galloway, McKetin, Kelly, and Leary (2009) likewise found 
only one quarter of dependent methamphetamine users in a sample from rural New 
South Wales received treatment for methamphetamine use in the past 12 months and 
less than half had ever received such treatment in their life time.  Kenny, Harney, 
Lee, and Pennay (2011) found that while 65% of their sample perceived the need for 
methamphetamine treatment, only 34% had sought treatment, including counselling, 
inpatient withdrawal, and attending Narcotics Anonymous.  In Victoria, it has been 
estimated that only around 6-11% of those requiring treatment for problematic 
methamphetamine use receive appropriate treatment (Ritter et al., 2003).     
Findings in relation to low levels of treatment access suggests barriers to 
accessing these services that need to be addressed.  One of the primary reasons for 
not seeking methamphetamine treatment in the Kenney et al. sample was not feeling 
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the need for formal treatment, often because they did not believe their drug use was 
serious enough, formal treatment was viewed as unnecessary, or their drug use was 
not considered a problem, despite their presentation sufficient to meet criteria for a 
DSM-IV diagnosis of methamphetamine dependence.  Those who reported treatment 
need but did not access it often reported they wanted to withdraw on their own, did 
not know how to go about accessing treatment, were unaware of treatment options, 
or wanted to keep using methamphetamine. 
Lack of perceived treatment need has been found a major barrier for 
accessing treatment for methamphetamine use despite dependence and experience of 
mental health problems (Wallace et al., 2009).  Cumming, Troeung, Young, Kelty, 
and Preen (2016) conducted a systematic review and meta-analysis of barriers to 
accessing treatment for methamphetamine use and found one of the most commonly 
cited barriers to accessing treatment as lack of perceived need, often due to not 
viewing use as problematic or enjoying use and lacking desire to cease using.  This 
suggests the importance of exploring the perceptions of methamphetamine and 
associated positive and negative experiences among people using the drug.  Australia 
was well represented in the study conducted by Cumming et al. (2016), with five of 
the eleven studies included being conducted in Australia.  Additional commonly 
cited barriers included desire to withdraw from methamphetamine alone, stigma and 
embarrassment, privacy and confidentiality concerns (Cumming et al., 2016).  
Practical barriers such as insufficient places, waiting lists, affordability, and lack of 
awareness of how to access treatment were also commonly reported (Cumming et 
al., 2016).  Cumming et al. (2016) also noted that services were often viewed as 
unsuitable or ineffective for methamphetamine, especially given strong focus of 
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treatment services on treatment for opioids, and staff attitudes toward individuals 
using methamphetamine were viewed as problematic.   
Similar barriers were noted by alcohol and other drug treatment workers from 
agencies across all States and Territories in Australia surveyed about the barriers 
they perceive for clients seeking withdrawal treatment for methamphetamine use in a 
study by Pennay and Lee (2009).  Many workers noted staff perceptions of 
methamphetamine use and appropriate treatment as a barrier to treatment, especially 
when this resulted in attempts to steer clients toward abstinence goals when the 
client may prefer an alternate outcome such as reduced use.  Despite staff 
perceptions being noted as a barriers, workers interviewed also often cited 
characteristics of methamphetamine users as one of the major barriers to treatment, 
suggesting the presence of some negative perceptions of this population (Pennay & 
Lee, 2009).  Many workers also noted lack of available services for people who use 
methamphetamine and limited spaces and waiting lists in those that are available.  
Also of concern was lack of pharmacological interventions for methamphetamine 
users, with more focus on opiates and alcohol (Pennay & Lee, 2009).    
  Issues of treatment access are particularly relevant in Tasmania, where 
access to drug related services vary greatly across the state.  For example, medically 
supervised detoxification services are only available in the South, despite 
detoxification typically being a requirement for entry to residential rehabilitation 
services (e.g., Missiondale; City Mission, 2015).  Thus, those in the rest of the state 
would either need to travel to the South for detoxification, or go through this without 
medical supervision.  As a result, it is possible that barriers to accessing treatment 
may differ across regions of Tasmania and understanding these patterns may assist in 
informing interventions to reduce barriers, increase access to treatment, and thereby 
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reduce harms experienced by individuals and the communities within which they 
live. 
The Current Study 
Given previous research, the aims of the current study are to: 1) examine the 
trends in injecting drug use in the north of the state and to compare this to data 
obtained in the south; and 2) explore potential barriers in accessing drug-related 
services and treatments among people who inject drugs in Tasmania and examine if 
these differ across regions.  In particular, the current study will focus on trends in 
relation to methamphetamine use and related harms, given increasing media, 
community, policy, and research attention in this substance in recent years.  Given 
findings that patterns of harm differ as a function of dependence on 
methamphetamine the current study will explore drug related patterns and harms 
among those not using methamphetamine, those using methamphetamine but who 
are not likely dependent on the drug, and those likely dependent on 
methamphetamine in both regions.       
Method 
Design 
The present study was exploratory in nature and involved face to face 
structured interviews with people in the north, north-west and south of Tasmania 
who frequently inject drugs.  The sample was deliberately non-representative, and 
was supplemented regional based analyses of existing indicator data sources.  This 
included needle and syringe program utilisation; information on police drug seizures 
and arrest; and data from the Illicit Drug Diversion Initiative (IDDI).  The nature of 
these indicator data sources will be described in further detail below.    
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Participants  
One hundred and forty-four people who injected drugs (PWID) on a monthly 
or more frequent basis, who had resided in the south (n = 100), north (n = 41), or 
north-west (n = 3) regions of Tasmania for the preceding 12 months participated in 
the interview component of the present study.  Participants were recruited through 
advertising (see Appendix A for example of flyers) at primary and secondary (i.e. 
pharmacies) needle and syringe program outlets, and snowball methods. Participants 
in southern regions were recruited within the existing IDRS survey. While this forms 
a convenience rather than a representative sample, this group of individuals have 
high levels of exposure to the illicit drug market and thus may be able to report on 
emerging trends (de Graaff, Peacock, & Bruno, 2014).  All participants were over 18 
years of age and provided informed consent to participate (see Appendix B for 
information sheet provided and Appendix C for copy of consent form used).  
Respondents were reimbursed $40 for their time. 
Instrumentation/Materials 
A streamlined version of the standardised Illicit Drug Reporting System 
(IDRS) survey including sections on demographics, drug use, price, purity, and 
availability of substances, crime, risk taking and physical and mental health was 
administered (see Appendix D).  Additional questions regarding treatment and 
treatment barriers; and perceptions of and experiences related to crystal 
methamphetamine use were included in the Tasmanian version of the survey (see 
Appendix E). The IDRS includes a number of standardised measures. In the current 
study, the Severity of Dependence Scale (SDS) for stimulant use; and the Kessler 
Psychological Distress Scale (K-10) were utilised.   
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The SDS is a measure of substance dependence and is able to screen for 
likely cases of diagnosable substance dependence with good sensitivity and 
specificity (Gossop et al., 1995).  It comprises five items pertaining to psychological 
components of dependence (e.g., did you ever think your use was out of control) 
measured on a four-point likert scale ranging from zero (never or almost never) to 
three (always or nearly always; Gossop et al., 1995). Higher scores are indicative of 
higher severity of substance dependence.  A cut-off score of four has been found to 
have good sensitivity and specificity in determining a DSM-III-R diagnosis of severe 
amphetamine dependence (Topp & Mattick, 1997). The PWID samples were classed 
into three groups based on their methamphetamine use, using SDS responses: no use 
in the past six months; methamphetamine use, not likely dependent; and 
methamphetamine use, likely dependent (4 or more on SDS).   
The K-10 is used to screen for psychological disorders and has strong 
psychometric characteristics for identification of those diagnosable with affective 
disorders (Kessler et al., 2002).  This measure comprises ten items, which ask about 
frequency of anxiety and depressive type symptoms over the past four weeks. Items 
are measured on a 5 point likert scale; scores of 10-15 indicate low distress; scores of 
16-21 moderate distress, scores of 22-29 high distress, and scores of 30-50 very high 
distress (Australian Bureau of Statistics [ABS], 2012).  Scores in the low range 
indicate the individual is likely not experiencing any psychological problems; in the 
moderate to high range they are likely experiencing mild to moderate problems that 
impact on their function; and in the very high range they are likely experiencing 
severe mental health problems (ABS, 2012).  Using the very high range (i.e. a cut-off 
score of 30) has been found to have a sensitivity of .24 and specificity of .99 in 
classifying those with a DSM-IV anxiety or affective disorder (Andrews & Slade, 
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2001).  The K10 has been found a reliable and valid tool in detecting affective 
disorders among individuals who inject substances, especially when higher cut-off 
scores (e.g., 27+) are used (Hides et al., 2007).  The present study will focus on 
scores in the very high range of distress.          
Procedure  
Respondents were asked to use a fake name when signing the consent from in 
order to ensure confidentiality was maintained, given the sensitive nature of 
information gathered.  Standardised interview processes for the IDRS survey were 
followed; with computer-assisted interviewing using Questionnaire Development 
System software. Interviews took place in private areas of primary needle and 
syringe program outlets.  Respondents were informed that they could opt out of 
answering any questions or sections of questions that they did not feel comfortable 
answering.  Risk assessments were conducted where necessary, and contact details 
of appropriate services provided as needed.     
Analysis 
IDRS Interviews with PWID 
Descriptive statistics (percentages) were applied to describe participant 
demographics, patterns of drug use, health and treatment barriers. Regional 
comparisons and comparisons among dependence groups were made using Chi-
Square Analysis, using Yates correction for continuity due to small sample sizes.  
When discussing days of use, medians are reported in preference to the mean due to 
extreme outliers inflating other measures of central tendency.  To determine if 
groups differed on variables described with medians Mann Whitney tests were used.  
When comparing scores within a group, Wilcoxon tests were utilised.     
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Indicator Data 
Indicator data was obtained for three locations in Tasmania: north; north-
west; and south.  Data pertaining to the north-west will not be explained below, as 
this was not included in the current study due to only three IDRS interviews being 
conducted in this area resulting in insufficient sample size in this region to make 
meaningful comparisons with other regions in Tasmania.   
Non-pharmacy Needle and Syringe Program utilisation.  Non-pharmacy 
(primary) Needle and Syringe Program outlets are services in the community which 
provide PWID with free clean injecting equipment to prevent reuse and sharing of 
equipment.  Individuals may also dispose of used equipment in these centres.  They 
also offer information on how to inject substances safely to reduce the likelihood of 
harm and may make referrals to other needed services such as accommodation, legal, 
health, mental health, and alcohol and drug services.  Monthly data was obtained 
from non-pharmacy needle and syringe program outlets: Anglicare (previously 
TASCHARD) Glenorchy and Hobart; Eastern Shore Community Health Centre 
(Clarence); and the Link Youth Health Service in the south; and the Salvation Army 
Launceston in the north for the financial years of 2008/09 through to 2014/15.  These 
sites collect information about the age, sex, drug usually or about to be injected, 
injecting equipment used, needle sharing, brief interventions and referrals of the 
individuals attending these sites.  There are some inconsistencies in how this data is 
collected across sites, making it difficult to make comparisons.  Due to some missing 
monthly data, some data was imputed.  Where possible, data was imputed from the 
average of the months in the same quarter.  If an entire quarter was missing the data 
was imputed from the preceding quarter, unless the preceding quarter was required 
to be imputed, in which case the subsequent quarter was used.  The 2008/09 data was 
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not included due to missing six months with no preceding data.  Data was imputed 
for the 2009/10 Salvation Army (5 months); 2011/12 Glenorchy (3 months); 2012/13 
Link (1 month), Glenorchy (5 months), and Hobart (5 months) datasets; and the 
2013/14 Link dataset (6 months).  All remaining monthly data was available, with 
the exception of 2013/14 Anglicare Glenorchy and Hobart dataset which is based on 
six-monthly figures.  In the 2014/15 dataset for Glenorchy and Hobart, the number 
of females for June 2015 was imputed due to apparent misreporting of data, whereby 
the number of females was noted to be exactly the same as the number of males, 
which was much larger than in any previous months.  Data for the southern sites was 
summed to obtain a south total.  Due to inconsistencies in recording of data the total 
number of people across age, sex, and drug type is not equivalent even where data 
was not imputed.  As a result, in order to obtain proportions, the highest number of 
these three categories was used as the denominator.  The age data from Link is 
missing in the final set due to use of a different age category system to the other 
sites.  Information on drug types was collapsed into three categories: 
methamphetamine type drugs; opioid type drugs; and other drugs.   
Tasmania Police seizure and arrest data.  Seizure and arrest data was 
provided by Tasmania Police for the financial years 2010/11-2014/15.  This provided 
information on the type and amount of drugs seized by police in each instance and 
consumer (charges related to use of illicit substances e.g., possession of substances) 
and provider (charges related to supply and manufacture of substances) drug-related 
arrests.  In order to use this data to make regional comparisons, postcodes were used 
to code each entry into north, north-west and southern regions of Tasmania.  This 
was done using the ABS Statistical Area Level 4 (SA4) A4 coding system (ABS, 
2011).  Where a postcode was located in two regions, it was coded as the one for 
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which a larger proportion of the coded area was located.  Postcodes that did not 
adhere to the ABS coding system were also excluded from summary statistics.  
Tasmania Police data was summed for each financial year in each location.    
Illicit Drug Diversion Initiative (IDDI).  IDDI is a scheme whereby 
individuals who are found using or in the possession of small amount of substances 
can be referred by police to drug and alcohol services for education and counselling.  
This initiative is mainly for first time drug offenders and diverts the individual away 
from attending court and possibly incurring criminal charges.  It is designed in an 
attempt to reduce problematic drug use and associated harms by encouraging 
treatment. Information about the type of drugs leading to referral is obtained and this 
was utilised in the current study.  Postcodes were coded into regions in the same way 
as that noted above for the Tasmania Police data.  Amphetamine type drugs 
(amphetamines not further defined, amphetamine, dexamphetamine, and 
methamphetamine) were collapsed into one category and this number was divided by 
the total number of diversions for each financial year to establish the proportion of 
methamphetamine related diversions.   
Results 
Demographics  
Overview of the PWID sample.  One hundred individuals from the southern 
(Hobart and surrounds) and 41 from the northern (Launceston and surrounds) 
regions of Tasmania were interviewed.  Three individuals were interviewed from 
north-west (Burnie) Tasmania and were excluded from analysis.  The demographic 
characteristics of the northern and southern samples are presented in Table 1 below.  
The mean age of respondents in the north was 38.5 years (SD = 7.8, range 18-55) 
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and 40.6 years (SD = 8.5, range 27-62) in the south.  Nearly two-thirds of both 
samples were male.   
In both samples more than two-thirds reported being unemployed, 84% in the 
south and 71% in the north.  Mean level of schooling completed in both samples was 
approximately 10 years.  Over two-thirds of the northern sample and over half of the 
southern sample went on to complete additional courses, particularly trade or 
technical qualifications.  Very few respondents in either sample had completed a 
university course.   
Approximately 15% (n = 15 south; n = 6 north) of both samples identified as 
Aboriginal and none identified as Torres Strait Islander.  The majority of both 
samples were born in Australia (97%, n = 97 south and 98%, n = 40 north).  The 
majority of both samples identified as heterosexual (96% in the south; 90% in the 
north).  Slightly less than half of both samples reported being in a relationship (either 
married/defacto or regular partner), with 55% (n = 23) of the northern sample and 
60% (n = 60) of the southern sample being single, separated or divorced   
The majority of respondents in both samples reported their main source of 
income in the past month as a government pension, allowance, or benefit (91%, n = 
91 in the south; 83%, n = 34 in the north).  A small proportion in the northern (12%, 
n = 5) and southern (2%, n = 2) samples reported their main source of income as 
criminal activity.  At time of interview, 10% (n = 10) of the southern sample and 
14% (n = 6) of the northern sample had unstable accommodation, including living in 
temporary accommodation (e.g., boarding house, hostel, shelter, hotel) or were 
homeless.   
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Table 1.  
Demographic Characteristics of the PWID Samples 
Characteristic North 
n = 41 
South  
n = 100 
Age (mean years, range) 38.5 (range 18-55) 40.6 (range 27-62) 
Sex (% male) 63 (26) 63 (63) 
Employment (%): 
Not employed 
Full time 
Part time/casual 
Student 
Home duties 
 
71 (29) 
2 (1) 
5 (2) 
5 (2) 
17 (7) 
 
84 (84) 
2 (2) 
8 (8) 
1 (1) 
4 (4) 
Received income from* (%): 
Wage/salary 
Government 
Criminal activity 
Child support 
 
5 (2) 
98 (40) 
20 (8) 
7 (3) 
 
9 (9) 
97 (97) 
10 (10) 
5 (5) 
Aboriginal (%) 15 (6) 15 (15) 
Education (mean no. years, range) 9.6 (range 4-12) 10.1 (range 5-12) 
Tertiary education (%): 
None 
Trade/technical 
University/college 
 
29 (12) 
66 (27) 
5 (2) 
 
45 (45) 
52 (52) 
3 (3) 
Notes. Figures in parentheses represent number of respondents. Only included responses where  
n > 1. * Sources of income in the past month.  Multiple responses were allowed.  
 
Overview of clients accessing Needle and Syringe Program outlets in 
Tasmania.  In both regions of Tasmania individuals accessing the non-pharmacy 
Needle and Syringe program outlets are predominately aged 30 or over, with smaller 
proportions of clients falling into younger age groups (with the exception of the Link 
which is a youth based service).  This pattern has been relatively consistent across 
the past six years in the north, as seen in Figure 1, although in the south it appears as 
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though the proportion of clients in the younger age ranges has been declining.  The 
mean ages of the current PWID samples of 39 years in the north and 41 years in the 
south appears relatively consistent with this pattern.  Similarly, clients accessing 
Needle and Syringe Program services, like those in the PWID sample, are 
predominately male in both the north and south of the state, as seen in Figure 2.    
      
Figure 1. Proportion of individuals in different age groups accessing non-pharmacy 
Needle and Syringe Program outlets in Tasmania by region, 2009/10-2014/15.  Notes. 
Those accessing the Link are missing as age ranges are categorised differently at this service.  
May not total 100% due to inconsistencies in data collection across sites.     
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Figure 2. Percentage of male clients of non-pharmacy Needle and Syringe Program 
outlets in Tasmania by region, 2009/10-2014/15.  Note. These rates have been imputed 
where necessary (see analysis section) due to missing data and inconsistencies in recording 
across sites.  
 
Drug Use History and Current Drug Use 
Table 2 reports on respondents’ history of injecting drug use, drug 
preferences and current patterns of use.  Methamphetamine was the most common 
type of drug first injected by participants in both samples.  Among northern 
respondents, methamphetamine, morphine (liquid or tablets), and morphine powder 
were preferred, with approximately one quarter of the sample noting each of these as 
their drug of choice.  In the south, morphine and methamphetamine were also 
commonly reported as drug of choice, along with opioid substitution medications.  
These same drugs are those which the majority of respondents reported that they 
injected most often in the past month. Chi-Square analysis revealed that a greater 
proportion of the northern than the southern sample reported injecting drugs daily or 
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more in the last month, χ2Yates (1) = 8.70, p = .003.  This was a small to moderate 
magnitude effect, Cramer’s V = .27.  Tables F1 and F2 in Appendix F provide 
detailed information about drugs used by respondents in both samples over the past 
six months.      
As can be seen in Figure 3, clients attending non-pharmacy NSP outlets have 
reported high proportions of amphetamine and opioid use in both regions over the 
years.  Data obtained from the PWID sample of high rates of amphetamine and 
opioid type drugs appears consistent with this.  It appears in the south, and to a lesser 
extent in the north, that there is a trend toward decreasing opioid use and increasing 
use of amphetamines.      
 
 
Figure 3. Drugs respondents reported they were about to use or last used when 
attending non-pharmacy NSP outlets.  Notes. Opioids include morphine, methadone, 
buprenorphine, oxycodone, heroin, and suboxone. Other drugs include steroids, cocaine, 
benzodiazepines, and any other drugs.  Some data missing due to inconsistencies in recording 
across sites – see analysis section for a description of how this data was imputed.    
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Table 2.  
Injecting Drug Use History, Drug Preferences, and Current Drug Use Patterns  
Variable North 
n = 41 
South 
n = 100 
Mean age at first injection (years) 19.5 (SD = 6.5) 
(range 13-39) 
21.2 (SD = 7.6) 
(range 10-55) 
First drug injected (%)   
Heroin 12 (5) 6 (6) 
Methamphetamine (any form) 71 (29) 59 (59) 
Speed 66 (27) 57 (57) 
Crystal  5 (2) 2 (2) 
Morphine 7 (3) 22 (22) 
Methadone 2 (1) 3 (3) 
Oxycodone 2 (1) 4 (4) 
Drug of choice (%)   
Cannabis 10 (4) - 
Heroin 10 (4) 16 (16) 
Methamphetamine (any form) 24 (10) 32 (32) 
Speed 7 (3) 23 (23) 
Crystal  17 (7) 9 (9) 
Morphine 27 (11) 26 (26) 
Methadone 2 (1) 19 (19) 
Morphine Powder 24 (10) - 
Drug injected most often in last month (%)   
Methamphetamine (any form) 32 (13) 39 (39) 
Speed 5 (2) 16 (16) 
Crystal  27 (11) 23 (23) 
Morphine 20 (8) 29 (29) 
Methadone 2 (1) 21 (21) 
Suboxone 7 (3) 3 (3) 
Subutex/Buprenorphine  2 (1) 4 (4) 
Morphine Powder 34 (14) - 
Pharmaceutical Stimulants - 3 (3) 
Most recent drug injected (%)   
Methamphetamine (any form) 26 (11) 39 (39) 
Speed 2 (1) 17 (17) 
Crystal  24 (10) 22 (22) 
Morphine 20 (8) 27 (27) 
Methadone 5 (2) 21 (21) 
Suboxone 7 (3) 3 (3) 
Subutex/Buprenorphine  2 (1) 7 (7) 
Morphine Powder 32 (13) - 
Frequency of injecting in last month (%)   
Not in the last month 0 1 (1) 
Weekly or less 24 (10) 24 (24) 
More than weekly, not daily 24 (10) 51 (51) 
Once a day 12 (5) 15 (15) 
2 to 3 times a day 39 (16) 9 (9) 
Note. Figures in parentheses represent number of respondents endorsing the item 
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Methamphetamine use.  Ninety-eight percent of both samples reported 
using at least one form of methamphetamine in the past (n = 98 south; n = 40 north), 
all of which had also injected methamphetamine in their lifetime.  Over two-thirds of 
both the northern (68%, n = 28) and southern (72%, n = 72) samples reported using 
methamphetamine in the past six months, all of which had also injected 
methamphetamine in the past six months.  Among those using methamphetamine, 
93% (n = 26) in the north reported the form they used most as crystalline, with the 
remainder citing powdered forms (n = 2).  In the south 58% (n = 42) reported 
crystalline as the form most commonly used, with the remaining 42% (n = 30) 
reporting they mostly used the powdered form.  Figure 4 displays proportion of 
respondents using various forms of methamphetamine and median days of use of 
these drugs in the past six month period.  As can be seen in Figure 4 this equates to 
nearly weekly use in both samples.       
 
 
Figure 4. Forms of methamphetamine used among PWID samples and median days 
of use 
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Table 3 displays the amount of methamphetamine used by respondents at any 
one time and on a typical day.  Respondents typically use less than a gram of 
methamphetamine at any one time or over the course of a day. 
Change in use of crystal methamphetamine over past 12 months.  
Respondents were asked whether they had made any changes in their use of crystal 
methamphetamine in the past 12 months.  Of those responding in the south (n = 60), 
the majority (47%, n = 28) reported using less often.  Approximately one-fifth 
reported using about the same (22%, n = 13) and a further one-fifth reported using 
more often (20%, n = 12).  Small proportions reported never using crystal 
methamphetamine (7%, n = 4); using for the first time in the past 12 months (3%, n 
= 2); and stopping use (2%, n = 1).  Of those responding in the north (n = 40), over 
one-third reported using less often (38%, n = 15), and a further fifth reported ceasing 
use (22%, n = 9).  Fifteen percent (n = 6) of the sample reported never using crystal 
methamphetamine; 13% (n = 5) reported no change in use; 10% (n = 4) reported 
increased use in the past 12 months; and a very small proportion reported using for 
the first time (3%, n = 1).  
Respondents who reported change in their use of crystal methamphetamine 
were asked the reasons for this.  As can be seen in Table 4, the most common reason 
for increased use was availability.  For those decreasing use, the effects of the drug 
while intoxicated, and effects on physical and mental health, and social relationships 
were commonly cited reasons.  Many respondents also reported there were other 
reasons for changes in their use.  Other reasons for increased use included: life 
stress/circumstances, and using instead of opiates.  For decreased use other reasons 
included:  preference toward powder methamphetamine, effects of the substance, 
wanting to control use, and perceptions of crystal methamphetamine.   
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Table 3.  
Median Amount of Methamphetamine Used in an Average Session, Most Used in a Session, and Median Amount Used on an Average day in the 
Past Six Months 
 North^ South 
Methamphetamine Form Average session Most session Average day Average session Most session Average day 
Powder       
Grams 0.25 (n = 5) 
(range 0.25-0.5) 
0.5 (n = 6) 
(range 0.5-1.0) 
0.5 (n = 7) 
(range 0.25-1.0) 
0.5 (n = 8) 
(range 0.5-1.0) 
1.0 (n = 12) 
(range 0.25-1.5) 
.9 (n = 10) 
(range 0.25-2.0) 
Points* 1.0 (n = 7) 
(range 1.0-2.0) 
1.25 (n = 6) 
(range 1.0-6.0) 
1.0 (n = 5) 
(range 1.0-3.0) 
1.0 (n = 39) 
(range 0.5-5.0) 
2.0 (n = 34) 
(range 0.5-5.0) 
1.0 (n = 37) 
(range 0.5-170.0) 
Crystalline (Points) 1.0 (n = 25) 
(range 0.25-3.0) 
2.0 (n = 22) 
(range 0.75-4.0) 
2.0 (n = 24) 
(range 0.25-12.0) 
1.0 (n = 57) 
(range 0.5-3.0) 
2.0 (n = 55) 
(range 0.5-5.0) 
1.0 (n = 57) 
(range 0.5-5.0) 
^Some respondents reported use in other measures e.g. dollars and these are not included.   Base methamphetamine not included due to small number of respondents.   
Only recorded crystalline in points due to low number of respondents for grams.  * 1 point = .1 gram
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Table 4.  
Reasons for Change in Crystal Methamphetamine Use in the Past 12 Months among 
Those Reporting Increased or Decreased Use.   
 North South 
 Increased use 
(n = 4) 
Decreased use 
(n = 23) 
Increased use 
(n = 12) 
Decreased use 
(n = 28) 
Curiosity - - - - 
Availability 50% (2) - 50% (6) 4% (1) 
Price - 4% (1) 17% (2) 25% (7) 
Purity - - 17% (2) 4% (1) 
Physical health - 22% (5) 8% (1) 43% (12) 
Mental health 25% (1) 22% (5) 8% (1) 25% (7) 
Social reasons - 9% (2) 25% (3) 25% (7) 
Don’t like effects - 26% (6) - 39% (11) 
Other reasons 50% (2) 57% (13) 17% (2) 14% (4) 
Notes. Decreased use includes both those reporting reduced use and cessation of use.  Multiple 
responses allowed.  Figures in parentheses represent number of respondents  
 
Among those reporting use of crystal methamphetamine use and answering 
this section (n = 53 south; n = 31 north), 13% (n = 7) in the south and 39% (n = 12) 
in the north reported reducing the amount they used at any one time in the past 12 
months.  Reductions in the number of days in a row that respondents used was also 
common, with 21% (n = 11) in the north and 58% (n = 18) in the south reporting this 
occurrence.  Reductions of how often crystal methamphetamine was used overall 
was also common, with 49% (n = 26) in the south and 58% (n = 18) in the north 
reporting this.   
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Tasmania Police Seizures of Methamphetamine  
Tasmania Police Seizures of drugs suspected to be methamphetamine are 
noted in Figure 5 below.  In the south, the number and weight of seizures has been 
fairly consistent over the past five years, with the exception of 2013/14 were there 
was a lower number of seizures at a greater weight.  In the north, the number of 
seizures has been increasing, with a notable rise in the number of seizures in the last 
financial year.  Weight of seizures in the north has fluctuated over the years.  
 
 
Figure 5. Seizures of methamphetamine by Tasmania Police, 2011/12-2014/15 in 
northern and southern Tasmania. Note. Units refers to seizure of methamphetamine 
tablets/capsules.     
 
 
 
 
67
87 84
132
392
88
110 119
36
100
116
135
4
113.5
90
326
18 15
0
500
1000
1500
2000
2500
3000
3500
4000
4500
5000
0
50
100
150
200
250
300
350
400
450
2010-
11
2011-
12
2012-
13
2013-
14
2014-
15
2010-
11
2011-
12
2012-
13
2013-
14
2014-
15
W
ei
gh
t 
o
f 
se
iz
u
re
s 
(g
ra
m
s)
N
o
. o
f 
se
iz
u
re
s/
u
n
it
s
North South
Total number of seizures
Total units
Weight (grams)
 
 
33 
 
Correlates of Health/Methamphetamine Related Harms  
Methamphetamine dependence.  The PWID samples were classed into 
three groups based on their methamphetamine use and stimulant SDS scores: no use 
in the past six months; methamphetamine use, not likely dependent; and 
methamphetamine use, likely dependent.  As can be seen in Table 5 the proportions 
of respondents falling into each category in the northern and southern samples were 
approximately equivalent. 
 
Table 5.  
Proportions of Respondents Classed as Dependent on Methamphetamine and 
Engagement in Use of Stimulants for 48 Hours or More without Sleep (Binge Use) 
Dependence category North 
n = 41 
South 
n = 94^ 
No methamphetamine use 27% (11) 28% (26) 
Methamphetamine use, not likely dependent  42% (17) 39% (37) 
 Binge use (%) 69% (11) 35% (12) 
Methamphetamine use, likely dependent  32% (13) 33% (31) 
Binge use (%) 52% (7) 52% (15) 
^ Note the smaller sample size in the south due to missing data, proportions based on available 
data. Figures in parentheses represent the number of respondents in each category         
 
In the southern sample, the median days of use of any form of 
methamphetamine in the past six months was significantly greater among those 
classed as likely dependent (Mdn = 55, range 2-180, n = 31) than those using 
methamphetamine but not likely dependent (Mdn = 15, range 1-180, n = 35), Mann-
Whitney U = 823.00, p < .001.  This was a moderate magnitude difference, r = .44.  
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In the northern sample, median days of use was not found to be significantly greater 
among those likely dependent on methamphetamine (Mdn = 26, range 2-180, n = 13) 
than those not likely dependent (Mdn = 16, range 5-60, n = 15), Mann-Whitney U = 
134.50, p = .088.  However, given that this was a moderate magnitude effect, r = .32, 
it may be that the sample size was not large enough to detect this difference.  
Extended periods of use.  Respondents commented on whether they had 
used stimulants or related drugs for 48 hours or more continuously without sleep.  Of 
those answering this section (n = 95 south; n = 40 north), 31% (n = 29) in the south, 
and 50% (n = 20) in the north reported engaging in this behaviour.  Table 5 notes the 
proportion of respondents engaging in this behaviour among those classed as likely 
and not likely dependent.  In the northern sample, 18% of those with no 
amphetamine use reported engaging in this behaviour, suggesting use of other 
stimulant type drugs.  Median number of times respondents engaged in this 
behaviour in the past six months was four in both samples (range 1-48 in both cases).  
These behaviours did not occur significantly more frequently among those likely 
dependent on methamphetamine (Mdn = 5, range 2-48 north; Mdn = 10, range 1-48 
south) than those not likely dependent (Mdn = 3, range 1-24 north; Mdn = 4, range 
2-12 south) in the northern, Mann-Whitney U = 51.50, p = .246, r = .28; or southern 
sample, Mann-Whitney U = 117.50, p = .183, r = .26.   
Mental health problems.  PWID participants were asked if they had 
experienced a mental health problem in the six months preceding the interview 
(Table 6). Of the 80 participants who commented in the south, 53% (n = 42) self-
reported experiencing a mental health problem in the past six months.  In the north, 
of the 37 participants who commented, 43% (n = 16) self-reported mental health 
issues.  Table 6 reports the specific mental health problems noted by respondents.  
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The most commonly reported mental health problems in both the north and south 
were depression and anxiety.  Nearly two-thirds of those likely methamphetamine 
dependent in the north reported mental health problems compared to one-third 
among those not using methamphetamine and those using but not likely dependent.  
Follow-up analyses indicated that mental health problems were not significantly 
more likely among those likely dependent compared to those not likely dependent, 
χ2Yates(1) = 1.17, p = .280, Cramer’s V = .28; and those not using methamphetamine, 
χ2Yates(1) = .81, p = .369, Cramer’s V = .30.  However, moderate magnitude effect 
sizes may suggest that while not significant, this difference may be meaningful.     
Psychological distress.  Experience of psychological distress, as indicated by 
scores on the Kessler Psychological Distress Scale (K-10), was common in both the 
northern and southern samples, with one-fifth of the northern sample and one-quarter 
of the southern sample scoring in the very high range.  Figure 6 displays proportion 
of respondents falling within each range of distress.     
In order to determine if respondents self-reported mental health problems 
matched a more objective indicator of psychological distress, the proportion of 
respondents who scored very high on the K-10 were compared to the proportion self-
reporting a mental health problem in both the northern and southern samples.  
However, chi-square analysis revealed no significant association between self-
reported mental health problems and scoring in the very high range of the K-10 in 
the northern, χ2Yates(1) = .70, p = .402, Cramer’s V = .20; or southern sample, , 
χ2Yates(1) = 1.76, p = .185, Cramer’s V = .18.           
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Table 6.  
Self-Reported Experience of Mental Health Issues and Access to Treatment over the Preceding Six Months 
 North South 
 Overall 
(n = 37) 
No meth. 
use 
(n = 9) 
Meth. use 
(n = 17) 
Meth. 
dependent 
(n = 11) 
Overall 
(n = 80) 
No meth. 
use 
(n = 22) 
Meth. use 
(n = 30) 
Meth. 
dependent 
(n = 22) 
% self-reporting mental health 
problem last 6 months 43% (16) 33% (3) 35% (6) 64% (7) 53% (42) 59% (13) 47% (14) 46% (10) 
% with K-10 score in very high range 21% (8) 0% 35% (6) 17% (2) 25% (21) 26% (6) 28% (9) 14% (3) 
% attending a health prof. for a mental 
health problem in past six months 
(among those reporting a problem) 50% (8) - 50% (3) 71% (5) 76% (32) 85% (11) 71% (10) 80% (8) 
Specific type of mental health 
problem experienced 
        
Depression 38% (6) 67% (2) 17% (1) 43% (3) 69% (29) 62% (8) 71% (10) 60% (6) 
Bipolar Disorder 6% (1) - 17% (1) - 7% (3) - 7% (1) 20% (2) 
Anxiety 44% (7) 33% (1) 33% (2) 57% (4) 71% (30) 54% (7) 79% (11) 70% (7) 
Panic - - - - 21% (9) 31% (4) 21% (3) 20% (2) 
Obsessive-Compulsive Disorder - - - - 2% (1) - - - 
Paranoia - - - - 5% (2) 15% (2) - - 
Schizophrenia 19% (3) - 33% (2) 14% (1) 10% (4) 15% (2) 7% (1) 10% (1) 
Drug-induced psychosis 6% (1) - - 14% (1) 5% (2) - 14% (2) - 
Post-Traumatic Stress Disorder 19% (3) - 50% (3) - 21% (9) 23% (3) 29% (4) 10% (1) 
Other 19% (3) - - 43% (3) 2% (1) - - - 
Note. Figures in parentheses represent number of respondents
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Figure 6. Proportion of respondents experiencing distress as indicated by scores on 
the Kessler Psychological Distress Scale. Note. Figures are based on those answering this 
section, as such, sample sizes may be lower.  Figures noted on the graph represent the number of 
respondents in each category.   
 
Treatment seeking behaviours for mental health problems.  Among those 
reporting recent experience of a mental health problem, 76% in the south (n = 32) 
and 50% in the north (n = 8) had recently attended a health professional in relation to 
mental health issues.  Participants had predominantly seen a general medical 
practitioner (81%, n = 26 south; 63%, n = 5 north), psychologist (41%, n = 13 south; 
13%, n =1 north), psychiatrist (25%, n = 8 south; 50%, n = 4 north) counsellor (20%, 
n = 6 south; 13%, n = 1 north), or a social worker (13%, n = 4; 13%, n = 1).  
Participants who self-reported a mental health problem but did not attend a health 
professional reported on the reasons for this.  Reasons for not attending included 
themes of: lack of perceived need, self-treatment, practical issues, and lack of 
understanding of treatment options.  Half of the northern participants (50%, n = 8) 
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and nearly two-thirds of the southern participants (60%, n = 25) self-reporting a 
mental health problem reported they had been prescribed medication for this in the 
preceding six months, including: antidepressants, benzodiazepines, and 
antipsychotics.   
Physical health.  Nearly two-thirds of both the southern (57%) and northern 
(64%) samples described their health in general as either good or better (see Figure 
7).  Those likely dependent on methamphetamine (67%) in the northern sample 
reported significantly higher proportions of poor or fair health than those who were 
using but not likely dependent on methamphetamines (18%), χ2Yates(1) = 5.25, p = 
.022, Cramer’s V = .50.  This was a large magnitude effect.  Those likely dependent 
did not report significantly higher proportions of poor or fair health than those not 
using methamphetamines (36%), χ2Yates(1) = 1.07, p = .300, Cramer’s V = .30, 
although this was a moderate magnitude effect.  In the southern sample, those not 
using methamphetamines (52%) had the highest proportion of self-reported poor or 
fair health, although this was not significantly greater than that seen in those using 
but not likely dependent (42%), χ2Yates(1) = .22, p = .638, Cramer’s V = .10 and those 
likely dependent on methamphetamines (32%), χ2Yates(1) = 1.27, p = .261, Cramer’s 
V = .20.   
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Figure 7. Respondents perceptions of their physical health in general.  Note. As some 
respondents answered some sections and not others there is some missing data within groups. 
 
Risk behaviours.  
Driving risk behaviours.  Among respondents who reported driving in the 
past six months, 79% (n = 38) in the south and 73% (n = 19) in the north reported 
driving while they believed they were still under the influence of illicit substances.  
Among these, 20% (n = 7) of the southern sample reported doing so daily, compared 
to 47% (n = 9) in the northern sample.  In the south, respondents reported driving 
while under the influence of illicit substances a median of 24 days (range 1-180 
days) in the past six months.  In the north, respondents did so a median of 120 days 
(range 1-180 days) in the past six months.  This difference was not significant, 
Mann-Whitney U = 428.00, p = .123, r = .21.  Table 7 displays reported illicit drugs 
taken prior to driving in the last six months and all illicit drugs taken the last time 
this behaviour occurred.  Crystal methamphetamine, morphine, and cannabis were 
commonly used by respondents prior to driving.  
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Table 7.  
Types of Drugs PWID Respondents were under the Influence of while Driving in the 
Past Six Months among those Driving and Using Drugs 
 North South 
Drug Last 6 
months 
(n = 19) 
Most recent 
(n =18)* 
Last 6 
months (n = 
37)* 
Most recent 
(n = 38) 
Methadone^ - - 14% (5) 13% (5) 
Suboxone^ 16% (3) 6% (1) - - 
Morphine^ 47% (9) 17% (3) 32% (12) 32% (12) 
Oxycodone^ 5% (1) - 11% (4) 8% (3) 
Powder 
methamphetamine 
16% (3) 6% (1) 20% (7) 8% (3) 
Base 
methamphetamine 
5% (1) - 5% (2) - 
Crystal 
methamphetamine 
42% (8) 33% (6) 38% (14) 29% (11) 
Cannabis 74% (14) 61% (11) 30% (11) 24% (9) 
Benzos^ 5% (1) - 16% (6) 8% (3) 
Other 47% (9) 33% (6) 8% (3) 5% (2) 
^Non-prescribed. * n = 1 responded don’t know to drugs used and not included. Multiple 
response allowed.  Unable to specify what other drugs were as this was not recorded. Only drugs 
where n > 1 are noted in the table.  Figures in parentheses represent number of respondents 
 
In the southern sample of drivers, all those dependent on methamphetamine 
(100%, n = 12) reported driving while under the influence of some form of illicit 
substance.  This behaviour was reported by slightly over two-thirds of those not 
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using methamphetamines (67%, n = 8) and those not dependent (76%, n = 16).  In 
the northern sample, 67% (n = 4) of those not using; 79% (n = 11) among those 
using but not likely dependent; and 67% (n = 4) of those likely dependent reported 
engaging in this behaviour.   
Activities undertaken while under the influence of methamphetamine.  
Respondents who had used crystal methamphetamine in the last 12 months were 
asked about their engagement in potentially dangerous and aggressive activities 
while under the influence of any methamphetamine.  Among those responding, 79% 
of individuals in the northern sample (n = 23) and 61% in the southern sample (n = 
32) reported engaging in at least one of these behaviours.  Table 8 reports 
proportions of individuals engaging in each specific activity in each sample.  In the 
north, engagement in these behaviours/activities was equally common among those 
dependent (85%, n = 11) and not dependent (79%, n = 11) on methamphetamine, 
χ2Yates(1) < .001, p = 1.000, Cramer’s V = .08; whereas in the south they were more 
common among those likely dependent (77%, n = 20) than those likely not 
dependent (43%, n = 10), χ2Yates(1) = 4.43, p = .035, Cramer’s V = .34.              
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Table 8.  
Proportion of Respondents Engaging in Dangerous Activities and Aggressive Behaviours while under the Influence of any Methamphetamine in 
the Last 12 Months (only asked of those reporting crystal methamphetamine use in the last 12 months) 
 North South 
 Overall 
n = 29 
Methamphetamine 
use 
n = 14 
Methamphetamine 
dependent 
n = 13 
Overall 
n = 52 
Methamphetamine 
use 
n = 23 
Methamphetamine 
dependent 
n = 26 
Worked 24 (7) 21 (3) 31 (4) 14 (7) 9 (2) 12 (3) 
Swam 21 (6) 21 (3) 23 (3) 15 (8) 13 (3) 15 (4) 
Drove 52 (15) 57 (8) 54 (7) 46 (24) 39 (9) 54 (14) 
Operated machinery 10 (3) 7 (1) 15 (2) 4 (2) 4 (1) 4 (1) 
Public disturbance 17 (5)  29 (4)  8 (1) 8 (4) 4 (1) 12 (3) 
Property damage 10 (3) 21 (3) - 12 (6) 4 (1) 19 (5) 
Stole 35 (10) 50 (7) 15 (2) 21 (11) 9 (2) 31 (8) 
Verbal abuse 41 (12) 50 (7) 31 (4) 25 (13) 17 (4) 31 (8) 
Physical abuse 14 (4) 14 (2) 15 (2) 10 (5) 9 (2) 12 (3) 
None of the above 21 (6)  21 (3)  15 (2) 39 (20) 57 (13) 23 (6) 
Note. Figures in parentheses represent number of respondents 
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Risk situations.  Respondents were asked about whether they had been 
verbally or physically assaulted or put in fear by someone under the influence of any 
form of methamphetamine in the past 12 months.  Of those responding in the south 
(n = 87) 46% (n = 40) reported at least one of these experiences, with 39% (n = 34) 
being verbally assaulted, 22% (n = 19) being physically assaulted, and 28% (n = 24) 
being put in fear.  Proportions were similar among those responding in the north (n = 
40) with 42% (n = 17) reporting at least one of these experiences; 43% (n = 17) 
reporting verbal assault, 20% (n = 8) physical assault, and 20% (n = 8) being put in 
fear.   Figure 8 displays the proportion of respondents reporting these experiences by 
their methamphetamine dependence status.   
 
 
Figure 8. Proportion of respondents reporting methamphetamine related risk 
experiences. 
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Criminal Activity and Law Enforcement  
Criminal activity in PWID sample.  Ninety-two respondents in the south 
and 38 in the north commented on criminal activity.  Forty-eight percent (n = 44) of 
those in the south and 58% (n = 38) of those in the north reported ever been in jail.  
In the south, 33% (n = 8) of those not using methamphetamine; 49% (n = 16) of 
those using but not likely dependent on methamphetamine; and 52% (n = 15) of 
those likely dependent on methamphetamine reported prison history.  In the north, 
these proportions were 50% (n = 5); 69% (n =11); and 50% (n = 6), respectively.  In 
the 12 months prior to interview, 34% of both samples (n = 31 south; n = 13 north) 
reported being arrested.  In the south 13% (n = 3) of those not using 
methamphetamine, 30% (n = 10) of those using and 55% (n = 16) of those likely 
dependent reported arrest.  In the north the proportions were 20% (n = 2); 63% (n = 
10); and 8% (n = 1), respectively.  As can be seen in Table 9 the most common 
reasons for arrest in the past 12 months in both samples was property crime and 
driving offences.  Respondents were also asked to comment on frequency of four 
different types of criminal activity in the past month.  Due to small sample sizes, 
variables were collapsed to represent no crime in the past month or any crime in the 
past month for each crime type.  As can be seen in Table 10, property crime and 
dealing were common among both samples, whereas fraud and violent crimes were 
reported less frequently.  A higher proportion of respondents in the north reported 
engaging in criminal activity in the past month than those in the south, χ2Yates(1) = 
6.45, p = .011, Cramer’s V = .24      
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Table 9.  
Reasons for Arrest in the Past 12 Months among those Arrested in the PWID 
Samples 
Reason for arrest North (n = 13) South (n =31) 
Use/possession of drugs 23% (3) 7% (2) 
Use/possession of weapons 8% (1) - 
Dealing/trafficking 15% (2) 3% (1) 
Property crime 39% (5) 36% (11) 
Fraud 15% (2) - 
Violent crime 8% (1) 19% (6) 
Driving offence 31% (4) 23% (7) 
Alcohol and driving - 16% (5) 
Drugs and driving 15% (2) 13% (4) 
Breach AVO - 3% (1) 
Other offence  8% (1) 13% (4) 
Note. Figures in parentheses represent number of respondents  
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Table 10.  
Crimes PWID Samples Reported Engaging in over the Past Month.   
 North South 
 Overall 
(n = 38) 
No use 
(n = 10) 
Use 
(n = 16) 
Dependent 
(n = 12) 
Overall 
(n = 92) 
No use 
(n = 24) 
Use 
(n = 33) 
Dependent 
(n = 29) 
Property crime 40% (15) 30% (3) 50% (8) 33% (4) 21% (19) 8% (2) 21% (7) 28% (8) 
Dealing  53% (20) 50% (5) 63% (10) 42% (5) 21% (19) 13% (3) 21% (7) 28% (8) 
Fraud - - - - 4% (4) - 3% (1) 7% (2) 
Violent crime 8% (3) 10% (1) 13% (2) - 3% (3) 4% (1) - 7% (2) 
Note. Figures in parentheses represent number of respondents  
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Law enforcement.  Table 11 reports on the proportion of drug-related arrests 
made by Tasmania police in the past five years that were methamphetamine related.    
Proportion of both consumer and provider offences that are methamphetamine 
related appear to have increased substantially in the past year across the state.   A 
similar pattern can be seen in the proportion of Illicit Drug Diversion Initiative 
(IDDI) diversions that are amphetamine related (see Figure 9).    Although, the 
proportion in the past year are still not as high as that seen in 2006/2007 in the south.  
 
 
Figure 9. Proportion of IDDI diversions that were amphetamine related 2006/07-
2015/16.  Note. Numbers noted on the Figure represent the number of amphetamine related 
diversions 
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Table 11.  
Proportion of Methamphetamine Related Offences among Drug-Related Arrests in Tasmania, 2010/11-2014/15 
 North South 
Year Consumer Provider Total Arrests^ Consumer Provider Total Arrests^ 
2010-11 3% (15) 6% (11) 4% (27) 3% (27) 17% (27) 5% (56) 
2011-12 5% (25) 16% (23) 7% (48) 5% (43) 17% (19) 6% (62) 
2012-13 5% (24) 12% (13) 6% (37) 6% (38) 17% (19) 8% (57) 
2013-14 4% (15) 25% (28) 8% (43) 2% (9) 7% (8) 2% (17) 
2014-15 20% (115) 40% (58) 24% (173) 11% (89) 27% (42) 13% (131) 
Note. Figures in parentheses represent number of arrests. Percentages are rounded to the nearest whole number and represent the proportion of all drug-related arrests 
in that area for that financial year that were methamphetamine-related. ^ This number may be greater than the sum of consumer and provider arrests due to the nature 
of some arrests not being specified   
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Perceptions of Methamphetamine among PWID 
The majority of respondents from both samples cited methamphetamine as 
the drug of most concern for their community (south: 72%, n = 68; north: 98%, n = 
39).  It was noted that in the northern sample all those citing methamphetamine as 
the drug of most concern specifically mentioned the crystal form.  A small 
proportion of the southern sample indicated excess use of alcohol as most 
problematic (17%, n = 16).   
Respondents who has used crystal methamphetamine in the past 12 months 
were asked to rate positive and negative experiences related to the use of crystal 
methamphetamine on a 10 point likert scale, where 0 = not at all and definitely = 10.  
There were six positive items and six negative items.  Scores were summed to give a 
total of positive and negative experiences score (range 0-60).  Median positive and 
negative scores are displayed in Figure 10.  Wilcoxon tests revealed that median 
negative and positive scores did not differ significantly among those using 
methamphetamine but not likely dependent in the south, T = 94.50, p = .465, r = -.16 
or the north, T = 34.00, p = .245, r = -.31.  The same was true of those likely 
dependent in the south, T = 95.00, p = .116, r = -.32, and in the north, T = 18, p 
=.099, r = -.46.  However, effect sizes were of moderate magnitude across both 
groups in the north, and the likely dependent group in the south, possibly suggesting 
a meaningful effect, with insufficient power to detect a significant difference.  Table 
12 displays dichotomised proportions of respondents endorsing particular items 
across dependence groups in each sample.  Substantial proportions of respondents 
across samples and dependence groups endorsed each of these items.      
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Table 12.  
Dichotomised Positive and Negative Experiences Related to Methamphetamine Use among those Using Crystal Methamphetamine in the Past 
12 Months  
 North South 
Responses ≥ 5 where 0= not at all; 10 = definitely  Overall 
(n = 29) 
Meth use 
(n = 14) 
Meth dep. 
(n = 14) 
Overall 
(n = 49) 
Meth use 
(n = 22) 
Meth dep. 
(n = 24) 
Increases my mood (makes me happy, confident) 69% (20) 71% (10) 69% (9) 80% (39) 82% (18) 79% (19) 
Increases pleasure from being with others 69% (20) 79% (11) 69% (9) 74% (36) 77% (17) 71% (17) 
Increases enjoyment from sex or physical activity 63% (17)^ 64% (9) 73% (8)^ 78% (38) 86% (19) 75% (18) 
Provides relief from unwanted thoughts, feelings, or moods 66% (19) 64% (9) 77% (10) 71% (30) 64% (14) 58% (14) 
Helps me work or perform 66% (19) 71% (10) 69% (9) 75% (36)* 81% (17)* 71% (17) 
Helps me cope with life 59% (17) 57% (8) 69% (9) 57% (27)^ 50% (10)^ 63% (15) 
Has unpleasant physical effects when intoxicated 31% (9) 36% (5) 23% (3) 33% (16) 46% (10) 21% (5) 
Has unpleasant psychological effects when intoxicated 48% (14) 57% (8) 39% (5) 45% (22) 55% (12) 42% (10) 
Makes me feel lousy in days after use 52% (15) 43% (6) 62% (8) 60% (29)* 68% (15) 57% (13)* 
Has unwanted effects on physical health 59% (17) 57% (8) 62% (8) 60% (29)* 64% (14) 61% (14)* 
Has unwanted effects on mental health 62% (18) 79% (11) 46% (6) 69% (33)* 68% (15) 70% (16)* 
Has negative effects on close personal relationships 69% (20) 71% (10) 69% (9) 73% (35)* 73% (16) 74% (17)* 
* n one lower than stated ^ n two lower than stated due to missing data (i.e. due to not being applicable or refusal to answer). Figures in parentheses represent number 
of respondents
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Figure 10. Median positives and negative of crystal methamphetamine use by region 
across dependence groups. 
 
Respondents were asked what their overall opinion of crystal 
methamphetamine was, rating it on a scale from -5 to +5 where -5 indicated it was a 
really terrible drug, 0 indicated a neutral opinion, and +5 indicated it was a really 
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participants who answered this question in the northern sample (n = 40) indicated a 
positive opinion of crystal methamphetamine.  In fact, the majority of the 
respondents in the northern sample reported it was a really terrible drug (-5: 82% in 
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dependent group; and 69% in the likely methamphetamine dependent group).  Only 
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Nearly a third of the southern sample reported a neutral (11%) or positive (19%) 
opinion of crystal methamphetamine.   
Opinions of crystal methamphetamine differed in the southern sample 
depending on their methamphetamine dependence status. Those not using 
methamphetamine displayed a lower proportion of neutral or positive ratings than 
either those using but not likely dependent on methamphetamine, χ2Yates(1) = 8.61, p 
= .003, Cramer’s V = .43; and those likely dependent on methamphetamine, χ2Yates(1) 
= 8.36, p = .004, Cramer’s V = .45.  Specifically, all but one (who reported a neutral 
opinion) of the participants who had not used methamphetamines in the last six 
months reported a negative opinion.  Of those using but not likely dependent 21% 
reported a neutral opinion and a further 21% a positive opinion, including 3% stating 
it as a really excellent drug.  Of those likely dependent 7% reported a neutral 
opinion, and 37% a positive opinion, with 18% considering crystal 
methamphetamine a really excellent drug.     
The majority of participants in both samples reported not approving of 
regular use (i.e. weekly) of crystal methamphetamine by an adult as shown in Table 
13.  In the northern sample, over two-thirds of those who did not use 
methamphetamines (73%) and those not likely dependent on methamphetamines 
(81%) reporting disapproving or strongly disapproving of this behaviour.  In the 
methamphetamine dependent group half endorsed such a view (54%), with the 
remainder reporting they neither approved nor disapproved of this behaviour.  In the 
southern sample similar disapproval was seen in the no methamphetamine use group 
(84%).  In the methamphetamine use, not likely dependent group over half (57%) 
disapproved or strongly disapproved, with 33% having a neutral opinion.  Over half 
the dependence group (53%), reported disapproval, although one fifth (22%) 
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reported approving or strongly approving of regular use of crystal 
methamphetamine.  Across all groups, very few respondents thought that their close 
friends would approve of them using crystal methamphetamine regularly if they 
were to do so (see Table 13).     
Access to Drug Treatment  
Current treatment.  At time of interview, 55% (n = 55) of the southern 
sample and 34% of the northern (n = 14) sample were currently in treatment for 
substance use.  The main form of treatment accessed in both samples was opioid 
substitution, including methadone, buprenorphine, and suboxone.  A small 
proportion in both samples were accessing drug counselling.  Figure 11 displays 
main form of treatment currently engaged in.   
In the southern sample none of the individuals who used methamphetamines 
were involved in drug counselling as their main form of current treatment.  Of those 
not using methamphetamines 12% (n = 3) reported drug counselling as their main 
form of current treatment.  In the north, only two participants noted drug counselling 
as their main form of treatment, one who had not used methamphetamines in the past 
six months, and one who used methamphetamines but was not likely dependent on 
them.  All of those likely dependent on methamphetamine, reported opioid 
substitution as their main form of current treatment.  
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Table 13. 
Proportions of Respondents Indicating Self and Other Approval of Regular Use (at least weekly) of Crystal Methamphetamine by an Adult 
 North South 
Opinion Overall No 
methamphetamines 
Not likely 
dependent 
Likely 
dependent 
Overall No 
methamphetamines 
Not likely 
dependent 
Likely 
dependent 
Self n = 40 n = 11 n = 16 n = 13 n = 89 n = 24 n = 33 n = 28 
Strongly 
approve 
- - - - 3% - - 11% 
Approve 3% - 6% - 6% - 6% 11% 
Neither 28% 27% 13% 46% 26% 17% 33% 21% 
Disapprove 15% 9% 25% 8% 20% 21% 27% 14% 
Strongly 
disapprove 
55% 64% 56% 46% 43% 63% 30% 39% 
Others^ n = 40 n = 11 n = 16 n = 13 n = 88 n = 24 n = 32 n = 28 
Strongly 
approve 
3% - 6% - 2% - - 7% 
Approve - - - - 2% - 3% 4% 
Neither 20% 9% 31% 15% 17% 8% 22% 21% 
Disapprove 5% - 6% 8% 34% 29% 47% 25% 
Strongly 
disapprove 
70% 82% 56% 77% 41% 63% 28% 36% 
Note. May not total 100% in all groups as some respondents indicated they did not know enough to say. ^refers to what respondent thought close friends’ perceptions 
would be of respondent using 
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Figure 11. Proportion of the PWID samples accessing a form of drug treatment at 
the time of interview. Note. Refers to main form of drug treatment (multiple responses were 
not allowed).  Opioid substitution includes methadone/biodone syrup, subutex/buprenorphine, 
suboxone 
 
Among those accessing treatment in the south, the majority reported finding 
out about their treatment from a GP referral (48%, n = 21) or from a friend/family 
member (34%, n = 15).  The remainder of those accessing treatment in the south 
found out from another service provider (15%, n = 6; including detox, drug and 
alcohol survives, hospital, and pain specialist), or were mandated to attend (5%, n = 
2).  In the north the majority reported other ways of finding out (54%, n = 7) 
including that they already knew about, had previously accessed, or could not 
remember.  Small proportions (15%, n = 2 in both cases) reported GP referral and 
friends/family.        
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Satisfaction with and perceptions of current treatment.  Respondents who 
were currently in treatment were asked how satisfied they were with their current 
treatment.  The majority of both samples were either satisfied or very satisfied with 
their current treatment, as displayed in Table 14.  However, one-fifth of those 
receiving treatment in northern Tasmania were dissatisfied or very dissatisfied with 
their treatment compared to only 2% in the south.  The majority of both samples 
accessing treatment indicated that they would recommend their treatment service to a 
friend (64% in the south and 77% in the north).  Although 11% in the south and 23% 
in the north reported they probably or definitely would not recommended the 
treatment.    
 
Table 14.  
Respondents Satisfaction with Current Treatment among those Currently in 
Treatment 
 North (n =13) South (n = 45) 
Very satisfied 46% 44% 
Satisfied 31% 47% 
Neutral - 7% 
Dissatisfied  15% - 
Very dissatisfied 8% 2% 
 
Respondents currently in treatment were asked qualitatively what was good 
and bad in regards to their current treatment.  Comments in both samples were made 
about how it is good being involved with professionals (e.g., doctor, pharmacist, 
psychologist) who care, are understanding and non-judgmental.  They also noted 
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increases in stability and functioning as a result of decreased drug use and crime, 
along with saving money.  In the south problems with treatment included: stigma, 
difficulty in picking up daily dose for those on opioid substitution programs (e.g., 
due to transport limitations, opening hours of chemist, waiting times), restrictions on 
their life (e.g., inability to go on holidays/visit family) due to need to be close to 
chemist and associating with people they do not want to at the chemist.  Those in the 
north also commented on difficulties of the opioid substitution program in regard to 
difficulty accessing and restrictions on life.  Difficulties with finances and payment 
processes were also noted. 
Treatment in the past six months.  In the southern sample, 56% (n = 56) 
reported accessing treatment for substance use in the past six months (including 
current treatment).  In the northern sample 46% (n = 19) reported accessing 
treatment in the past six months.  Table 15 reports proportions of engagement in 
treatment services over the six months prior to interview.  Opioid substitution was 
the most common form of treatment in both samples, although small proportions in 
both samples reported accessing drug counselling in the past six months.  No 
participants in either sample reported accessing naltrexone treatment, detoxification, 
a therapeutic community or Narcotics Anonymous in the previous six months.    
As can be seen in Table 15, engagement in either no treatment or opioid 
substitution programs were the predominant patterns of access to treatment across 
dependence categories.  Very few respondents were engaged in drug counselling in 
the previous six months, irrespective of dependence status.   
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Table 15.  
Proportion of Respondents Accessing Drug Treatment in Past Six Months  
 North South 
Type of 
Treatment 
Overall No 
methamphet. 
Not likely 
dependent 
Likely 
dependent 
Overall No 
methamphet. 
Not likely 
dependent 
Likely 
dependent 
None 54% (22) 64% (7) 35% (6) 69% (9) 44% (44) 42% (11) 46% (17) 48% (15) 
Opioid 
substitution 
39% (16) 27% (3) 59% (10) 23% (3) 53% (53) 54% (14) 51% (19) 52% (16) 
Drug 
counselling 
17% (7) 9% (1) 24% (4) 15% (2) 10% (10) 15% (4) 3% (1) 13% (4) 
Other - - - - 2% (2) 4% (1) 3% (1) - 
Note. Multiple responses could be selected.  Includes current treatment.  Figures in parentheses represent number of respondents. Methamphet = methamphetamine.   
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Attempts to access treatment.  A small proportion of the southern sample (9%, n 
= 9) and nearly one-fifth of the northern sample (17%, n = 7) reported attempts to access 
treatment in the six months prior to interview without success.  Table 16 summarises the 
types of services respondents had tried to access.  One of the most commonly reported 
problems was the waiting list, particularly in the north where all but one reported this as 
the reason for their unsuccessful attempt to access.  Additional problems included 
financial constraints and other practical issues (e.g., staff availability).  The majority of 
both samples indicated that they were not currently waiting for treatment (96%, n = 96 
south; 90%, n = 37 north), with nearly a quarter of the northern sample reporting they 
had given up on seeking treatment (24%, n = 10) compared to only 1% in the south.   
Half of the southern sample (49%, n = 46 of 96 answering the question) reported 
they had not tried to access treatment in the last six months because they were already in 
treatment, and 45% (n = 42) because they were not interested in treatment.  In the north 
one-fifth (20%, n = 8 0f 40 answering the question) reported not trying to access 
treatment due to current engagement and two-thirds (68%, n = 27) reported they were 
not interested in treatment.  Respondents were asked what the main reasons were for not 
being interested in treatment.  As seen in Table 17, while a relatively low proportion of 
northern respondents reported that they did not need treatment, this may be accounted 
for by many citing other reasons for not being interested in treatment such as they would 
be able to cease themselves without treatment.  As other reasons were the most 
commonly reported reasons for not being interested in treatment in the north and a 
quarter of those in the south, these are described below. 
 
 
 
 
60 
 
Table 16.  
Proportion of Respondents Attempting to Access Treatment Services in the Past Six 
Months without Success    
Treatment service tried to access  North South 
General Practitioner 0 3 
Alcohol, Tobacco, and Other Drugs Worker 2 0 
Counsellor 2 0 
Psychologist 0 0 
Psychiatrist 0 0 
Opioid substitution  10 4 
Therapeutic community 0 2 
Detoxification 7 2 
Other 0 1 
Note. Multiple responses were allowed.  
Other reasons noted for lack of interest in treatment included: belief can/desire to 
do it themselves, this was particularly commonly noted in the north; restrictions 
associated with treatment; use not problematic; lack of/belief in available treatment 
options (e.g., for stimulant dependence); and practical issues (e.g, waiting list, other 
commitments).  
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Table 17. 
Reasons given by Respondents for not being Interested in Treatment.    
 North (n = 27) South (n = 40*) 
Don’t need treatment 19% 63% 
Don’t know of any 
services 
- 3% 
Stigma or embarrassment - 3% 
No places available 4% - 
Can’t afford treatment 4% 5% 
Services too far away 4% 3% 
Other reasons 70% 25% 
* n = 2 of those not interested in treatment did not answer this question  
 
Ease of access to drug treatment.  Participants were asked to report on the ease 
of access to drug treatment if they wanted it.  Approximately two-thirds of both samples 
indicated it would be difficult or very difficult (67% south, 63% north).  In the north 
nearly one third indicated it would be easy or very easy (29%) and 12% in the south 
thought it would be easy, with none indicating it would be very easy.  The remaining 
participants reported they did not know how easy it would be to access treatment.  
Perceptions of difficulty in accessing treatment (excluding those responding “don’t 
know”) differed among the dependence groups in the north.  A significantly lower 
proportion of those likely dependent on methamphetamines (27%, n = 3) reported it 
would be difficult or very difficult to access drug treatment than those using 
methamphetamines but not likely dependent (77%, n = 13), χ2Yates(1) = 4.75, p = .029, 
Cramer’s V = .49; and those not using methamphetamines (100%, n = 10), χ2Yates(1) = 
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8.87, p = .003, Cramer’s V = .75.  Those not using methamphetamines were not found to 
differ significantly from those not likely dependent on methamphetamines, although this 
was a moderate magnitude effect, χ2Yates(1) = 1.21, p = .271, Cramer’s V = .32.  In the 
south, those dependent on methamphetamines (78%, n = 18) were not significantly less 
likely to report it would be difficult or very difficult to access treatment than those using 
methamphetamines but not likely dependent (86%, n = 24), χ2Yates(1) = .11, p = .745, 
Cramer’s V = .10 and those not using methamphetamines (91%, n = 20), χ2Yates(1) = .58, 
p = .448, Cramer’s V = .18.  Nor was there any difference found regarding perceptions 
of ease of access to drug treatment between those not using methamphetamines and 
those using but not likely dependent, χ2Yates(1) = .02, p = .902, Cramer’s V = .08.    
Discussion 
The results of the present study are consistent with previous IDRS extension 
studies (Bruno, 2004; de Graaff & Bruno, 2007) across Tasmania where different 
patterns of drug use and associated risks and health outcomes were found in different 
areas of the state.  Specifically, the current study found that a higher proportion of those 
in the north reported injecting drugs daily or more often in the past month than those in 
the south.  A high proportion of northern respondents also reported commonly using 
morphine powder, a finding that was not noted in the south.  Additionally, higher 
proportions of those in the north reported engaging in criminal activity over the past 
month than those in the south.     
Patterns among dependence groups also appeared to differ in the different 
geographical areas under study.  These differences are outlined in further detail below.  
Overall, differences found support the arguments of de Graaff et al. (2014) and 
Degenhardt, Sara, et al. (2016) of the importance of investigating patterns of use, 
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associated harms, and treatment access across geographical areas rather than 
generalising findings across regions.  If policy makers and treatment providers are 
making decisions based on the data obtained within one geographical area this may 
prevent needs being appropriately met due to lack of consideration of specific nuances 
among different populations of people who inject drugs in Tasmania. 
Methamphetamine Use and Related Trends 
In the current study, methamphetamine use was commonly reported among 
respondents in both samples, particularly the crystalline and powdered forms.  Use of 
methamphetamine was estimated to be approximately weekly within both samples.  
Needle and Syringe Program data suggested a trend toward decreasing opioid use and 
increasing methamphetamine use, particularly in the south of the state, although 
methamphetamine use has remained consistently higher in the north than in the south 
across years.  In the north, Tasmania Police seizures of substances suspected to be 
methamphetamine have increased in recent years in the north, with a more stable pattern 
seen in the south.  In the past year methamphetamine related arrests have increased 
across the state, as well as methamphetamine related diversions under the Illicit Drug 
Diversion Initiative.  However, of note is the fact that these rates are not as high as those 
seen in 2006/07 in the south of the state.  Additionally, it is important not to assume that 
these shifts in indicator data represent an epidemic of methamphetamine use as claimed 
by the media (Usher et al., 2015).  This is because many of these patterns could also 
reflect a shift in focus of law enforcement agencies toward methamphetamine, 
particularly given community concern (Degenhardt, Sara, et al., 2016).   
Within the samples interviewed it was evident that methamphetamine use was 
not a new phenomenon, as the majority of both samples reported methamphetamine as 
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the first drug they injected.  The results of the current study are consistent with national 
data that suggests that shifts toward crystalline over powdered forms of 
methamphetamine is not a new phenomenon (Degenhardt, Sara, et al., 2016; Stafford & 
Burns, 2015).  Specifically, very small proportions of respondents indicated using the 
crystalline form for the first time in the past 12 months.  In fact, within the samples 
interviewed the majority reported mostly reducing or ceasing use of the crystalline form 
in the past 12 months, suggesting shifts away from use of this form of methamphetamine 
across the state of Tasmania among people who inject drugs.  However, these findings 
may not apply to other populations of people who use drugs in Tasmania, such as those 
not injecting, and younger individuals.  For example, Degenhardt, Larney, et al. (2016) 
noted that patterns of methamphetamine use differed across age groups, with younger 
age groups displaying higher rates of dependent use, with this increasing over the years.  
They suggested that this may be due to older individuals have more likely developed a 
more negative opinion of methamphetamine, than younger individuals who have had 
less exposure to the negative effects of and harms associated with problematic use.   
Differences between Dependence Groups in Use and Related Harms  
As would be expected, those classed as likely dependent in the southern sample 
reported more frequent use of methamphetamine than those using but not likely 
dependent.  In the north, this finding was not significant, although the effect size was of 
moderate magnitude.  This may suggest that results were consistent with expectations 
but the current study was underpowered to detect this difference.  Engaging in extended 
periods of use of stimulant and related drugs was commonly reported across both 
methamphetamine groups in both the northern and southern samples.  This behaviour 
did not occur more frequently among those likely than those not likely dependent in 
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either sample.  This suggests that binge use and associated risks may not always be 
limited to those likely meeting criteria for a methamphetamine use disorder.  This 
pattern of binge use is problematic as it is associated with physical and psychological 
harms, even if the same amount of methamphetamine is consumed overall.  For 
example, Cheng et al. (2010) and Semple, Patterson, and Grant (2003) found binge use 
to be associated with increased self-reported physical health and mental health problems; 
higher levels of depressive symptoms; weight loss; sleep difficulties; and hallucinations 
and paranoia compared to those using the same amount of methamphetamine within 30 
days but not engaging in binge use.  Additionally, animal studies have found binge use 
to increase cardiovascular stress and to be associated with heart problems (Varner, 
Ogden, Delcarpio, & Meleg-Smith, 2002).    
Mental health problems, particularly anxiety and depression were commonly 
reported in both samples, across dependence groups. While not a significant finding, 
moderate magnitude effect sizes may suggest that self-reported mental health problems 
are more common among those likely dependent on methamphetamine than those not 
likely dependent on methamphetamine and those not using methamphetamine in the 
north.  This would be consistent with previous research that has found co-morbid 
disorders to be common among those using methamphetamine, and particularly among 
those dependent on this drug (e.g., Akindipe et al., 2014; Glasner-Edwards et al., 2010b; 
Salo et al., 2011).  High rates of self-reported mental health problems across dependence 
categories suggests that this is a common occurrence among individuals engaged in 
poly-injecting drug use in Tasmania.  Common experience of psychological distress and 
self-reported mental health conditions among people who inject drugs, and those likely 
dependent on methamphetamine found in the current and previous studies suggests the 
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need for drug and alcohol services to provide integrated care (Akindipe et al., 2014).  
Additionally, when clients present to mental health settings with co-morbid substance 
use issues it is important that clinicians assess for such issues and intervene where 
necessary.  This is particularly relevant given the association of co-morbid disorders and 
symptoms with poorer treatment substance use and mental health outcomes among those 
seeking treatment for methamphetamine dependence found in previous research (e.g., 
Glasner-Edwards et al., 2009; Glasner-Edwards et al., 2010a).  Thus, without 
considering and addressing mental health concerns when engaging individuals in drug 
treatment, treatments are unlikely to be effective.     
If clinicians in both mental health and drug and alcohol settings do not assess for 
and intervene in both domains, clients may not receive needed treatment.  Kay-Lambkin, 
Baker, and Lewin (2004) describe how clients with co-morbid mental health and 
substance use issues often find themselves “stuck on the roundabout” due to lack of 
service integration and being passed from one service to the other with possibly 
conflicting advice.  Miller and Brown (1997) argue that psychologists are well placed to 
intervene both in the area of metal health and substance use, particularly because 
theoretical maintaining factors in substance use disorders are similar to those in mental 
health problems and respond to the same type of treatment approaches with which 
psychologists are already familiar.  For example, in regard to methamphetamine use 
disorders, psychosocial interventions and in particular cognitive behaviour therapy and 
motivational interviewing have been found efficacious in reducing use and associated 
problems (Baker, Kay-Lambkin, Lee, Claire, & Jenner, 2003; Baker et al., 2004; 
Ciketic, Hayatbakhsh, Doran, Najman, & McKetin, 2012; Karila et al., 2009; Lee & 
Rawson, 2008).  In a randomised control trial, Baker et al. (2006) found ten sessions of 
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combined motivational interviewing and cognitive behaviour therapy to improve 
depressive symptoms at 6 month follow-up and amphetamine use at 12 month follow-up 
compared to treatment as usual.  Despite evidence that psychologists can be effective 
working with clients with substance use problems using the same therapeutic modalities 
as used with other common disorders, there may be some barriers that need to be 
overcome in this regard that may prevent professionals from provided needed integrated 
care.  For example, Mundon, Anderson, and Najavits (2015) found that clinical 
psychology graduate level doctoral students in America endorsed more negative 
emotional reactions, such as feeling overwhelmed and frustrated, when responding to 
vignettes about a client with alcohol or cocaine use disorder than to a client with major 
depressive disorder.  They argue the importance of providing education about and 
exposure to clients substance use during psychology training, as increased experience 
was associated with less negative emotional reactions.  Studies in America (é.g., 
Harwood, Kowalski, & Ameen, 2004) have found that less than half of mental health 
professional receive training in substance use disorders through coursework or practical 
placements.  It is important that such training occur, as there is evidence (e.g., Hughes et 
al., 2008), that training in dual diagnosis of substance use and interventions and 
associated supervision can improve practitioners knowledge and self-efficacy to work in 
this area.       
  The lack of significant association between self-reported mental health 
problems and psychological distress scores in the very high range may suggest lack of 
insight regarding the nature of symptoms.  Conversely, as there was typically a lower 
proportion reporting very high distress than those reporting a mental health problem it 
may be that among people who inject drugs their perceived mental health status is lower 
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than their objective mental health status.  Additionally, the fact that many individuals 
self-reporting mental health problems attended a health professional in this regard may 
suggest that they have already received treatment that has reduced the severity of their 
symptoms, thereby resulting in a lower psychological distress score than if the problem 
was left untreated. The majority of respondents self-reporting a mental health problem in 
the south attended a health professional in this regard.  In the north only half of those 
self-reporting a mental health issue sought professional support.  Common reasons cited 
for not seeking treatment included lack of perceived need, engaging in self-treatment via 
substance use, practical issues and lack of knowledge/understanding of available 
treatment options.  In the Netherlands, Vanheusden et al. (2008) similarly found that 
perceived lack of seriousness of mental health problems, lack of knowledge about 
treatment options, and lack of belief in the efficacy of professional treatment were major 
barriers to accessing services for mental health issues.  Bohon, Cotter, Kravitz, Cello, 
and Garcia (2016) found similar results in a sample of college students in America and 
argued that this implies the importance of educating individuals about the nature of 
mental health problems and associated treatment options to shift attitudes in this regard.  
The fact that individuals in the present study reported self-medicating for their perceived 
mental health problems suggests that these issues are distressing enough for them to 
consider intervening.  It would be important to educate individuals about the impact of 
substance use on mental health to promote understanding that this may not be the most 
effective solution to their difficulties.   
For those in the south education around mental health, the impact of substance 
use on mental health, and treatment options may be largely facilitated by general 
practitioners as the majority of individuals self-reporting mental health problems did 
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attend their general practitioner in this regard.  In the north, this may be slightly more 
complex as many individuals did not attend a health professional when subjectively 
experiencing a mental health problem.  This suggests the importance of other 
professionals who have contact with PWIDs in the north in providing this education.  
For example, Needle and Syringe Program staff may be able to facilitate this as they 
already provide education, brief intervention and referral for problems related to 
substance use and mental health.  It may be possible to train such staff to briefly screen 
for problematic substance use and mental health problems when clients present to these 
services.  Evidence suggests that non-specialist staff can learn to assess and offer brief 
intervention for problematic substance use (e.g., Amanda Baker & Velleman, 2009) and 
that staff in drug and alcohol settings can be trained to screen for mental health problems 
(e.g., Lee et al., 2011).  Additionally, staff may be able to use motivational interviewing 
strategies to promote engagement with treatment services for substance and mental 
health issues.  There is evidence that such a strategy (using motivational interviewing) is 
effective for promoting engagement in opioid substitution treatment among those with 
opioid use problems (Roberts, Annett, & Hickman, 2010), and this may be applied to 
promoting engagement with other needed treatment services.  Additionally, promoting 
community awareness of mental health issues, substance use issues, and treatment 
options more generally (e.g., through psychoeducational brochures and adverting) may 
also assist in shifting the attitudes of the community more generally.      
Additionally, self-medication among the PWIDs samples suggests that focus on 
development of more adaptive problem focused coping styles may be an integral part of 
therapeutic intervention, as self-medication suggests a reliance on an avoidant/emotion-
focused style of coping.  Using substances to self-medicate mental health symptoms 
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such as anxiety and depression may provide temporary relief, and thereby results in the 
substance use becoming negatively reinforced and increasing the likelihood of this 
strategy being repeated when symptoms re-occur (Kronenberg, Goossens, van 
Busschbach, van Achterberg, & van den Brink, 2015).  Researchers (e.g., A'zami, 
Doostian, Mo'tamedi, Massah, & Heydari, 2015; Kronenberg et al., 2015) have found a 
greater tendency toward avoidant/emotion-focused styles of coping among those with 
substance use disorders than individuals without, who tend to use a more problem 
focused coping style.  An avoidant coping orientation when experiencing cravings and 
high risk situations had been associated with increased alcohol use and dependence five 
years after treatment, although this association is lower in individuals with a greater 
sense of self-efficacy to remain abstinent (Levin, Ilgen, & Moos, 2007).  It is likely that 
similar patterns apply to other substances and suggests the importance of equipping 
individuals with skills to cope with cravings and manage high risk situations in an active 
way to promote their sense of efficacy to maintain therapeutic goals.            
Consistent with results of the systematic review conducted by Darke et al. 
(2008), respondents in the north who were classed as likely dependent on 
methamphetamine reported poorer physical health than those using but not likely 
dependent.  This is likely because those likely dependent engage in higher frequency of 
use, which is associated with poorer physical health outcomes (Darke et al., 2008).  
Additionally, those dependent on methamphetamine may be more likely to spend more 
of their income on drugs rather than on other necessities such as food and health care.  In 
the south this pattern was not found, with no difference in self-reported physical health 
across dependence categories, although slightly over half of the southern sample in 
general reported poor or fair physical health.  It is not clear why physical health did not 
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differ as a function of dependence in the southern sample.  However, as respondents 
were not asked about engagement with health services for physical health, it may be that 
those in the south are more likely to seek treatment for physical health problems.  There 
is some evidence that those in the south may engage with general practitioners more 
often than those in the north, given that in the south respondents usually found out about 
substance use treatment from their general practitioner, whereas this occurred rarely in 
the north.  Further research would be needed to clarify this finding.     
Among both samples, driving under the influence of substances was common, in 
particular methamphetamine, morphine, and cannabis.  Given the effects of substances 
on cognitive function (e.g., Darke et al., 2008; Scott et al., 2007) this behaviour is has 
the potential to put the individuals and others at risk.  Engagement in other risky 
behaviours and/or aggressive behaviours whilst under the influence of crystal 
methamphetamine was equally common among those likely dependent and not likely 
dependent in the north but was more common among those likely dependent in the 
south.  This suggests that for those in the north risk is associated with use of crystal 
methamphetamine generally.     
Positive and negative effects of crystal methamphetamine 
High proportions of respondents endorsed that crystal methamphetamine has negative 
mental and physical effects and impacted negatively on relationships.  Respondents also 
reported several positive effects of crystal methamphetamine and in the north, 
particularly among those who were likely dependent there was a trend toward positives 
outweighing negatives.  Regardless of this imbalance, the high levels of reported 
negative effects has important implications for treatment.  Specifically, further exploring 
the negative effects of crystal methamphetamine noted may promote ambivalence and 
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change talk within a motivational interviewing framework (Miller & Rollnick, 2013).  
Being aware of the positive aspects of using crystal methamphetamine is also important 
for clinicians, as these may represent barriers to treatment and making behavioural 
changes (Miller & Rollnick, 2013).  Understanding that clients hold both positive and 
negative views of crystal methamphetamine use may assist the clinician in facilitating 
the exploration of pros and cons when using a decisional balance sheet with clients, a 
technique which has been found to be strongly related to alcohol and drug outcomes 
among clients receiving motivational interviewing (Apodaca & Longabaugh, 2009).      
Perceptions of methamphetamine 
Perceptions of methamphetamine among respondents in the current study where 
largely negative.  The majority of respondents in both samples noted methamphetamine 
as the drug of most concern for their community despite high levels of recent 
methamphetamine use within the samples.  Within the general population of Australia 
2013 National Household Survey data found methamphetamine to be the drug ranked 
third highest in regard to community concern, following alcohol and tobacco (Australian 
Institute of Health and Welfare, 2014).  
No respondents in the north reported a positive opinion of crystal 
methamphetamine when asked to rate the drug, with most reporting it as a really terrible 
drug regardless of dependence status.  In the south opinions were also largely negative, 
however, unsurprisingly those using methamphetamine regardless of dependence status 
had a higher proportion of neutral or positive opinions than those not using 
methamphetamine.  The majority of both samples regardless of dependence status also 
reported disapproving of regular use (weekly) of crystal methamphetamine by an adult.  
This is consistent with findings of the National Household survey in Australia, where 
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even amongst those using methamphetamine recently, less than 20% approved of this 
behaviour (Australian Institute of Health and Welfare, 2014).  In general, respondents in 
the current study also believed that their friends would disapprove of them using 
methamphetamine regularly (regardless of whether or not they were engaged in this 
behaviour).   
Previous studies have similarly found a negative opinion/attitude toward 
methamphetamine among people who inject drugs.  For example, Darke and Torok 
(2013) asked individuals who injected drugs regularly (weekly or more) to rate how 
harmful they thought each of the major drug classes were and whether they should be 
decriminalised with minor penalties (e.g., monetary fines) or legalised (i.e. no legal 
penalties).  Among this sample, over two-thirds had used methamphetamine in the past 
six months, however, only 9% supported legalisation and 27% supported 
decriminalisation, with nearly two-thirds stating methamphetamine should continue to 
be prohibited.  Methamphetamine was also perceived to be the most harmful of the illicit 
substances, rated as significantly more harmful that cocaine, MDMA, heroin, and 
cannabis (Darke & Torok, 2013).  Likewise, Lancaster, Sutherland, and Ritter (2014) 
found that over half of the 2011 IDRS cohort from across Australia opposed or strongly 
opposed the legalisation of methamphetamine, despite this being the drug of choice cited 
by many respondents.  Additionally, over one-third of this cohort supported increased 
penalties for sale or supply of methamphetamine, regardless of whether 
methamphetamine had been used recently (Lancaster, Ritter, & Stafford, 2013) 
Overall, among varied samples of individuals who inject drugs in the current and 
previous studies, attitudes toward methamphetamine are overwhelmingly negative.  
Despite high levels of negative opinions about methamphetamine, and in particular the 
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crystalline form in the present study it can be assumed that very few respondents in the 
likely dependent group are accessing treatment for their methamphetamine use, as most 
were in opioid substitution programs only.  Given negative opinions by self and others 
regarding methamphetamine use it might seem surprising that individuals within these 
samples continue to use these substances (although there was some evidence of 
decreased use of the crystalline form within these samples).  The Theory of Planned 
Behaviour (Ajzen, 1991) may be able to explain this occurrence.  This model posits that 
two of the key influences on behavioural intention, which in turn predicts actual 
behaviour, are the individual’s attitude toward the behaviour and their perceptions of 
others’ attitudes toward the behaviour (subjective norm).  These factors were evident in 
the current study.  However, an additional influence on behavioural intention and also on 
actual behaviour is the individual’s belief that they can engage in the desired behaviour 
(perceived behavioural control).  Thus, it may be that individuals within the current 
study continue to use methamphetamine despite negative attitudes towards the behaviour 
and perceived negative attitudes of peers because they do not believe they are able to 
make changes to their use.  However, this explanation does not account for all results 
noted, given that one of the major barriers to accessing treatment in the current study 
was perceptions that one would be able to cease taking substances without professional 
support.  It may be that perceptions of the efficacy of formal treatment and attitudes and 
subjective norms toward treatment are also at play.  Some respondents did appear to lack 
awareness of available treatment options for stimulant dependence, and some did not 
believe that treatment would work for them.  Additionally, perceived behavioural control 
over ability to access treatment if needed may be low in the current samples, as the 
majority thought it would be difficult or very difficult to access drug treatment if they 
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wanted it.  Thus, increasing awareness of available services, how to access them, and the 
effectiveness of this may be an important step to enhancing perceived behavioural 
control.        
Access to treatment and treatment barriers 
Engagement with drug treatment services was relatively common in the present study 
with slightly over half in the south and slightly under half in the north reporting 
accessing treatment in the past six months.  The majority of respondents accessing 
treatment across dependence categories were accessing only opioid substitution 
programs, with very few accessing drug counselling, irrespective of likely 
methamphetamine dependence.  This is problematic, because at present evidence-based 
treatment for methamphetamine use disorder is primarily psychological, with very little 
evidence available for the efficacy of pharmacological treatments (Ciketic et al., 2012; 
Karila et al., 2009; Lee & Rawson, 2008).  This suggests that among certain groups of 
people who inject multiple drugs across Tasmania individuals who likely require 
psychological support are not accessing these services when needed.   
Findings of engagement mainly in opioid substitution programs is consistent 
with previous research in other areas of Australia.  For example, in Melbourne, Kenny et 
al. (2011) found engagement in opioid substitution programs common among 
individuals dependent on methamphetamine.  Similarly, in rural New South Wales, 
Wallace et al. (2009) likewise found that opioid pharmacotherapy was the predominant 
form of drug treatment engaged in by dependent and regular methamphetamine users.  
Only one quarter of those classed as methamphetamine dependent in their sample has 
received treatment for methamphetamine use in the past 12 months.  Wallace et al. 
(2009) noted that this was often due to low perceived need for treatment and lack of 
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motivation to engage in treatment.  They theorised that this may be due to being engaged 
in pharmacotherapy for opioid use, as individuals may fear disclosing other drug use due 
to possible restrictions on their dose.  Wallace et al. (2009) also argue that individuals 
may be less likely to consider their methamphetamine use problematic, as the 
withdrawal from these substances is less acute than from opioids. Degenhardt, Sara, et 
al. (2016) discuss how current harm reduction policies are largely focused on opioid 
injectors and there is need to consider services for individuals using methamphetamine 
separately.  This problem of focus on opioid substitution has also been noted by drug 
and alcohol workers across Australia as one of the barriers to accessing appropriate 
treatment for methamphetamine use (Pennay & Lee, 2009).  
Many respondents in both samples reported that they were not interested in 
accessing treatment.  This appeared to be largely due to respondents believing that they 
did not need treatment, often in the north because they believed if they wanted to cease 
using substances they could do so on their own without professional support.  It is 
important to note that these findings may not refer specifically to methamphetamine use, 
as respondents were asked about access to treatment more generally given the 
exploratory nature of this study.  However, among previous studies (e.g., Kenny et al., 
2011; Wallace et al., 2009) of individuals with methamphetamine dependence, a lack of 
perceived need for formal treatment due to perceived lack of seriousness of their drug 
use; perceived lack of problems associated with use; or belief that formal treatment is 
unnecessary has been reported.  Likewise, in a meta-analysis, belief that treatment was 
not necessary and desire to withdraw from methamphetamine without treatment were 
among the most commonly cited barriers for accessing treatment for methamphetamine 
use (Cumming et al., 2016).  Kenny et al. (2011) found that respondents would often 
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attempt to withdraw without professional support and often with the aid of other illicit 
drugs or prescription medications.  Cumming et al. (2016) argue that this suggests the 
importance of professionals involved with individuals who use methamphetamine 
offering information about methamphetamine dependence, treatment options available 
and the benefits of this to ensure individuals understand that self-withdrawal from the 
substance alone is not likely to promote longstanding change.     
Limitations of the current study 
There are several limitations that should be noted for the current study.  Firstly, 
the small sample size in the north and across dependence groups may have resulted in 
the study being underpowered to detect differences across groups.  This may be seen at 
times by moderate effect sizes that may indicate meaningful differences across groups, 
but lack of statistical significance of these findings.  If possible, future research in 
Tasmania should employ a larger sample size to follow-up findings of the current study.   
Secondly, as the nature of the current study was exploratory and followed the 
IDRS protocol, questions were targeted to patterns of drug use more generally rather 
than being specific to methamphetamine use.  This means that often it may be difficult 
to determine whether associated harms are specifically related to patterns of 
methamphetamine use or to other patterns of drug use, particularly given high level of 
polydrug use within the samples.  However, prior research (e.g., Kenny et al., 2011; 
Wallace et al., 2009) that has focused specifically on regular and dependent levels of 
methamphetamine use also used samples that engaged in high levels of polydrug use.  It 
appears that engagement in polydrug use is more common than engaging in use of a 
single drug alone, and that research into treatment barriers and outcomes for 
methamphetamine should also consider the impact of polydrug use.  In the current study, 
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it is not possible to determine whether the barriers noted for treatment access are 
methamphetamine specific and further research could consider asking questions in 
relation to methamphetamine treatment.  However, it seems likely that there is some 
relevance of these barriers noted to access to methamphetamine treatment, especially as 
the same barriers have been noted in previous research (e.g., Cumming et al., 2016; 
Kenny et al., 2011; Pennay & Lee, 2009; Wallace et al., 2009).          
Thirdly, the findings of the current study cannot be generalised to all individuals 
who use substances across Tasmania.  For example, only two geographic regions were 
explored, findings may not apply to individuals who use other routes of administration 
of drugs (i.e. do not inject drugs), and younger samples of people who use drugs.  
Degenhardt, Sara, et al. (2016) note that one of the limitations of the IDRS protocol is 
that it does tend to recruit only older individuals who have used substances for a long 
period of time and may miss the emergence of newer drug trends among younger 
populations.  While the IDRS is deliberately not representative and aims to examine 
trends in the drug market and associated risks and harms within a group with high level 
exposure to the illicit drug market (de Graaff et al., 2014), it is important to be cautious 
in generalising the findings of such research.    
Finally, it is possible given that the majority of the data in the present study is 
based on the self-report PWIDs that these may be some biases in the conclusions drawn.  
For example, respondents may have difficulty recalling accurately information about 
their drug use that occurred many years ago and may also be reluctant to respond 
honestly to questions which they may perceive as having impact (e.g., about crime) if 
they were truthful and about behaviours that may not be socially desirable.  This concern 
was partially offset in the current study by allowing respondents to skip sections or 
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specific questions that they did not feel comfortable to answer honestly.  Furthermore, 
Darke (1998) reviewed the literature of the psychometric properties of the self-report of 
PWIDs and found self-reported current and past drug use, engagement in injecting risk 
behaviours, and criminal activity to display good reliability even up to 10 years and 
displayed good concurrent validity with objective measures of these variables.     
Conclusions     
In conclusion, the present study demonstrated differences in patterns of drug use, 
associated harms, and access to treatment services between northern and southern 
regions of Tasmania.  This suggests that policy and service provision decisions across 
Tasmania should be informed by research in that particular geographic area and not 
confined to data collected in the south as part of the IDRS.  High levels of mental health 
problems, poor physical health, criminal activity, exposure to violence, and engagement 
in risk taking behaviours were noted in the current study.  Some of these harms were 
more pronounced among those likely dependent on methamphetamine, suggesting the 
need to consider whether an individual’s drug use is at a problematic level rather than 
generalising finding to all individuals using methamphetamine.   
Despite a high proportion of individuals being classed as likely dependent on 
methamphetamine in both samples and negative perceptions about this substance, very 
few were accessing forms of treatment found efficacious for this substance.  Generally, 
respondents were engaged in treatment for opioid use only.  One of the major barriers to 
accessing treatment in the current study was lack of perceived treatment need often due 
to belief in capacity to cease using without formal treatment or perceived lack/efficacy 
of formal treatment.  While it is not clear in the current study if these barriers pertain 
specifically to methamphetamine use it does suggest the importance of educating 
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individuals who inject drugs about available treatment options should self-withdrawal 
prove ineffective.  Similar barriers were noted for seeking treatment for mental health 
problems, suggesting again the need for service providers to provide information to 
clients.  For example, often in needle and syringe program outlets clients are provided 
with brief intervention, in this setting it may be possible to provide brief 
psychoeducation around impacts of substance use on mental and physical health; 
available treatment options and how these work.  Further research is needed around 
specific barriers to accessing drug treatment in Tasmania and what factors may assist in 
overcoming these, as it is evident that many individuals who likely require formal 
treatment are not accessing needed services.  Additionally, when clients present to 
psychologists for mental health problems it is important that they assess and treat 
substance use problems given that clients often have co-morbid difficulties and may be 
using substances to self-medicate.  Clients are likely to achieve poorer mental health and 
substance use outcomes if integrated treatment service provision does not occur.        
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Appendices 
Appendix A: Example of Flyers used to Advertise Study to PWIDs 
 
 
 
  
 W  A  N  T  E  D  
 
 
Researchers would like to talk 
 to people who inject drugs  
such as morphine, speed,  
benzos or methadone.   
 
Participants will be reimbursed $40 
for their time. 
 Interviews will be held at: 
 Salvation Army Launceston NSP 
 
Please text or phone 0401179495 for 
more information. 
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Appendix B: Information Sheet 
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Appendix C: Consent Form 
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Appendix D: IDRS Interview  
Please refer to data USB or electronic submission for this document. 
Note highlighted questions were not asked in the northern branch of the current study. 
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Appendix E: Additional IDRS Questions Tasmania 
Please refer to data USB or electronic submission for this document. 
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Appendix F: Polydrug use history tables (Tables F1-F2) 
Table F1. Polydrug use history of the PWID sample North (N = 41) 
Drug Class Ever 
used 
% (n) 
Ever 
injected 
% (n) 
Used last 
6 months 
% (n) 
Injected 
last 6 
months 
% (n) 
Smoked 
last 6 
months 
% (n) 
Snorted 
last 6 
months 
% (n) 
Swallowed 
last 6 
months 
% (n) 
Days 
used 
last 6 
months 
Days 
injected 
last 6 
months 
Heroin 76 (31) 73 (30) 15 (6) 15 (6) 0 0 0 9 9 
Homebake heroin 29 (12) 27 (11) 5 (2) 5 (2) 0 0 0 2 2 
Any heroin (inc. homebake) 76 (31) 73 (30) 15 (6) 17 (7) 0 0 0 6 6 
Methadone (prescribed) 63 (26) 42 (17) 20 (8) 12 (5)   20 (8) 168 48 
Methadone (not prescribed) 61 (25) 59 (24) 22 (9) 22 (9)   7 (3) 6 4 
Physeptone (prescribed) 20 (8) 15 (6) 5 (2) 5 (2) 0 0 5 (2) 14 12 
Physeptone (not prescribed) 46 (19) 37 (15) 5 (2) 5 (2) 0 0 2 (1) 8 5 
Any methadone (inc. 
physeptone) 
81 (33) 76 (31) 37 (15) 32 (13) 0 0 24 (10) 62 24 
Buprenorphine (prescribed) 24 (10) 15 (6) 2 (1) 2 (1) 0 0 2 (1) 46 1 
Buprenorphine (not 
prescribed) 
56 (23) 42 (17) 15 (6) 12 (5) 2 (1) 0 5 (2) 13 6 
Any buprenorphine (exc. 
Buprenorphine-naloxone) 
63 (26) 46 (19) 15 (6) 12 (5) 2 (1) 0 7 (3) 22 7 
Buprenorphine-naloxone 
tablet (prescribed) 
17 (7) 7 (3) 0 - - - - - - 
Buprenorphine-naloxone 
tablet (not prescribed) 
24 (10) 17 (7) 0 - - - - - - 
Buprenorphine-naloxone film 
(prescribed) 
32 (13) 12 (5) 20 (8) 7 (3) 0 0 17 (7) 90 90 
Buprenorphine-naloxone film 
(not prescribed) 
37 (15) 27 (11) 20 (8) 17 (7) 2 (1) 0 0 22 23 
Any buprenorphine-naloxone 63 (26) 34 (14) 32 (13) 20 (8) 2 (1) 0 17 (7) 95 72 
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Table F1. Polydrug use history of the PWID sample North (N = 41) (continued) 
Drug Class Ever 
used 
(%) 
Ever 
injected 
(%) 
Used last 
6 months 
(%) 
Injected 
last 6 
months 
(%) 
Smoked 
last 6 
months 
(%) 
Snorted 
last 6 
months 
(%) 
Swallowed 
last 6 
months 
(%) 
Days 
used 
last 6 
months 
Days 
injected 
last 6 
months 
Fentanyl 20 (8) 17 (7) 2 (1) 2 (1) 0 0 0 1 1 
Oxycodone (prescribed) 24 (10) 12 (5) 15 (6) 10 (4) 0 0 10 (4) 30 25 
Oxycodone (not prescribed) 81 (33) 73 (30) 37 (15) 34 (14) 0 0 7 (3) 5 6 
Any oxycodone  85 (35) 76 (31) 44 (18) 37 (15) 0 0 15 (6) 11 10 
Morphine (prescribed) 34 (14) 20 (8) 0 - - - - - - 
Morphine (not prescribed) 83 (34) 81 (33) 54 (22) 51 (21) 0 0 5 (2) 39 48 
Any morphine (exc. powder) 88 (36) 81 (33) 54 (22) 51 (21) 0 0 5 (2) 39 48 
Over the counter codeine 85 (35) 2 (1) 37 (15) 0 0 0 37 (15) 12 - 
Other opioids (not elsewhere 
classified) 
88 (36) 2 (1) 29 (12) 0 0 0 29 (12) 6 - 
Speed powder 95 (39) 95 (39) 34 (14) 34 (14) 2 (1) 0 0 5 5 
Base/point/wax 42 (17) 39 (16) 15 (6) 12 (5) 2 (1) 0 0 3 3 
Ice/shabu/crystal 88 (36) 85 (35) 68 (28) 68 (28) 27 (11) 0 0 13 12 
Amphetamine liquid 42 (17) 39 (16) 2 (1) 2 (1)   0 4 4 
Any form methamphetamine 98 (40) 98 (40) 68 (28) 68 (28) 29 (12) 0 0 23 20 
Pharmaceutical stimulants 
(prescribed) 
7 (3) 7 (3) 2 (1) 2 (1) 0 0 0 48 48 
Pharmaceutical stimulants 
(not prescribed) 
71 (29) 59 (24) 29 (12) 24 (10) 0 0 5 (2) 4 6 
Any form pharmaceutical 
stimulants 
71 (29) 59 (24) 29 (12) 24 (10) 0 0 5 (2) 4 6 
Cocaine 61 (25) 29 (12) 12 (5) 2 (1) 0 10 (4) 0 1 1 
Hallucinogens 59 (24) 10 (4) 5 (2) 0 0 0 5 (2) 4 - 
Ecstasy 66 (27) 32 (13) 10 (4) 2 (1) 0 0 7 (3) 4 2 
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Table F1. Polydrug use history of the PWID sample North (N = 41) (continued) 
Drug Class Ever 
used 
(%) 
Ever 
injected 
(%) 
Used last 
6 months 
(%) 
Injected 
last 6 
months 
(%) 
Smoked 
last 6 
months 
(%) 
Snorted 
last 6 
months 
(%) 
Swallowed 
last 6 
months 
(%) 
Days 
used 
last 6 
months 
Days 
injected 
last 6 
months 
Alprazolam (prescribed)  22 (9) 12 (5) 7 (3) 2 (1) 0 0 7 (3) 40 56 
Alprazolam (not prescribed) 61 (25) 42 (17) 37 (15) 20 (8) 0 0 20 (8) 4 2 
Other benzodiazepines 
(prescribed) 
54 (22) 2 (1) 29 (12) 0 5 (2) 0  27 (11) 90 - 
Other benzodiazepines (not 
prescribed) 
59 (24) 12 (5) 39 (16) 2 (1) 0 0 39 (16) 8 1 
Any benzodiazepines 88 (36) 56 (23) 66 (27) 22 (9) 5 (2) 0 63 (26) 34 4 
Seroquel (prescribed) 24 (10) 2 (1) 7 (3) 0 0 0 7 (3) 163 - 
Seroquel (not prescribed) 44 (18) 7 (3) 15 (6) 0 0 0 15 (6) 2 - 
Any Seroquel  61 (25) 7 (3) 22 (9) 0 0 0 22 (9) 3 - 
Alcohol 100 (41) 15 (6) 63 (26) 0   63 (26) 6 - 
Cannabis 100 (41)  90 (37)  90 (37)  0 180  
Inhalants 17 (7)  0     -  
Tobacco 100 (41)  98 (40)     180  
E-cigarette 42 (17)  32 (13)     2  
Steroids 17 (7) 12 (5) 7 (3) 5 (2) 0 0 2 (1) 10 6 
Other drugs 88 (36) 88 (36) 71 (29) 71(29) 0 0 0 24 24 
Morphine powder 85 (35) 85 (35) 71 (29) 71 (29) 0 0 0 24 24 
Drugs mimicking effects of 
amphetamines or cocaine  
10 (4) 10 (4) 5 (2) 5 (2) 0 0 0 2 2 
Drugs mimicking effects of 
cannabis 
17 (7) 0 7 (3) 0 7 (3) 0 0 1 - 
Note. Figures in parentheses represent number of respondents. Days used = median and are rounded to the nearest whole number.  
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Table F2. Polydrug use history of the PWID sample South (N = 100)  
Drug Class Ever 
used 
%  
Ever 
injected 
%  
Used last 
6 months 
%  
Injected 
last 6 
months 
%  
Smoked 
last 6 
months 
%  
Snorted 
last 6 
months 
%  
Swallowed 
last 6 
months 
%  
Days 
used 
last 6 
months 
Days 
injected 
last 6 
months 
Heroin 56 55 5 5 0 0 0 3 3 
Homebake heroin 14 14 1 1 0 0 0 5 5 
Any heroin (inc. homebake) 57 56 6 6 0 0 0 4 4 
Methadone (prescribed) 52 45 33 25   29 180 60 
Methadone (not prescribed) 66 65 20 20   0 11 11 
Physeptone (prescribed) 14 12 1 1 0 0 1 1 1 
Physeptone (not prescribed) 64 63 29 29 0 0 3 5 5 
Any methadone (inc. 
physeptone) 
85 82 48 43 0 0 30 178 41 
Buprenorphine (prescribed) 22 9 6 3 0 0 4 180 180 
Buprenorphine (not 
prescribed) 
31 28 13 12 0 0 2 3 3 
Any buprenorphine (exc. 
Buprenorphine-naloxone) 
47 34 18 15 0 0 5 34 3 
Buprenorphine-naloxone 
tablet (prescribed) 
10 4 0 - - - - - - 
Buprenorphine-naloxone 
tablet (not prescribed) 
13 8 3 2 0 0 1 24 14 
Buprenorphine-naloxone film 
(prescribed) 
16 3 10 1 0 0 10 180 180 
Buprenorphine-naloxone film 
(not prescribed) 
19 16 12 11 0 0 2 9 6 
Any buprenorphine-naloxone 41 22 21 13 0 0 12 120 14 
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Table F2. Polydrug use history of the PWID sample South (N = 100) (continued) 
Drug Class Ever 
used 
(%) 
Ever 
injected 
(%) 
Used last 
6 months 
(%) 
Injected 
last 6 
months 
(%) 
Smoked 
last 6 
months 
(%) 
Snorted 
last 6 
months 
(%) 
Swallowed 
last 6 
months 
(%) 
Days 
used 
last 6 
months 
Days 
injected 
last 6 
months 
Fentanyl 6 3 1 1 0 0 1 10 8 
Oxycodone (prescribed) 22 18 1 1 0 0 1 32 2 
Oxycodone (not prescribed) 76 75 27 25 0 0 3 5 6 
Any oxycodone  80 78 28 26 0 0 4 6 6 
Morphine (prescribed) 29 24 5 5 0 0 2 180 180 
Morphine (not prescribed) 93 92 47 47 0 0 5 48 48 
Any morphine (exc. powder) 96 94 48 48 0 0 6 48 48 
Over the counter codeine 63 4 24 1 0 0 24 12 6 
Other opioids (not elsewhere 
classified) 
55 6 17 2 0 0 15 13 6 
Speed powder 95 93 49 49 1 1 0 12 12 
Base/point/wax 34 32 9 9 1 0 0 6 5 
Ice/shabu/crystal 79 75 59 57 12 1 3 18 20 
Amphetamine liquid 32 31 3 3   0 1 1 
Any form methamphetamine 98 98 72 72 12 2 3 23 22 
Pharmaceutical stimulants 
(prescribed) 
7 4 2 2 0 0 0 13 13 
Pharmaceutical stimulants 
(not prescribed) 
65 62 25 25 0 0 3 12 12 
Any form pharmaceutical 
stimulants 
67 64 26 26 0 0 3 12 11 
Cocaine 48 34 2 2 0 1 1 8 4 
Hallucinogens 69 17 8 4 0 0 5 1 1 
Ecstasy 71 24 7 4 0 1 4 2 1 
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Table F2. Polydrug use history of the PWID sample South (N = 100) (continued) 
Drug Class Ever 
used 
(%) 
Ever 
injected 
(%) 
Used last 
6 months 
(%) 
Injected 
last 6 
months 
(%) 
Smoked 
last 6 
months 
(%) 
Snorted 
last 6 
months 
(%) 
Swallowed 
last 6 
months 
(%) 
Days 
used 
last 6 
months 
Days 
injected 
last 6 
months 
Alprazolam (prescribed)  28 9 3 0 0 0 3 180 - 
Alprazolam (not prescribed) 61 37 21 9 0 0 16 5 7 
Other benzodiazepines 
(prescribed) 
64 7 38 1 0 0 38 180 96 
Other benzodiazepines (not 
prescribed) 
65 17 45 7 0 0 41 24 35 
Any benzodiazepines 87 49  66 14 0 0 62 140 24 
Seroquel (prescribed) 25 2 7 0 0 0 7 180 - 
Seroquel (not prescribed) 32 1 9 2 0 0 7 5 4 
Any Seroquel  51 3 14 2 0 0 12 7 4 
Alcohol 95 3 46 0   46 10 - 
Cannabis 95  73  73  3 170  
Inhalants 26  2     3  
Tobacco 99  97     180  
E-cigarette 40  26     5  
Steroids 4 3 0 - - - - - - 
Other drugs 4 3 0 - - - - - - 
Drugs mimicking effects of 
amphetamines or cocaine  
33 31 15 14 0 1 0 10 13 
Drugs mimicking effects of 
cannabis 
13 0 2 0 1 0 1 4 - 
Note. Number of respondents are the same as percentages noted in the table. Days used = median and are rounded to the nearest whole 
number.  
